{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":41,"total_is_capped":false,"direct_labels_cover":0,"predictions_cover":41,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12","author_layer_release":"2026-06-26"},"query_hash":"c3179db2e965","filters":{"venue":"Immuno-Oncology Technology"}},"results":[{"id":"W4405375041","doi":"10.1016/j.iotech.2024.100746","title":"117O Stereotactic body radiotherapy (SBRT) with pembrolizumab (pembro) for unresected stage I/II non-small cell lung cancer (NSCLC): The randomized, double-blind, phase III KEYNOTE-867 study","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Lung Cancer Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke","funders":"","keywords":"Pembrolizumab; Medicine; Lung cancer; Stage (stratigraphy); Oncology; Medical physics; Internal medicine; Cancer; Immunotherapy; Biology","authors":[{"name":"Andreas Pircher","is_ca":false},{"name":"Szabolcs Soter","is_ca":false},{"name":"Michael A. W. Eaton","is_ca":false},{"name":"G. Galffy","is_ca":false},{"name":"D. Kowalski","is_ca":false},{"name":"Atsushi Hata","is_ca":false},{"name":"Abdhiel Bustamante-Navarrete","is_ca":false},{"name":"Nikolaj Frost","is_ca":false},{"name":"E. Levchenko","is_ca":false},{"name":"Mariana P. Monteiro","is_ca":false},{"name":"Anoop Haridass","is_ca":false},{"name":"M. Bouchard","is_ca":true},{"name":"M.V. Bluthgen","is_ca":false},{"name":"M-J. Ahn","is_ca":false},{"name":"B.G.M. Hughes","is_ca":false},{"name":"Amy C. Durham","is_ca":false},{"name":"Yiquan Xu","is_ca":false},{"name":"Ayman Samkari","is_ca":false},{"name":"A. Song","is_ca":false},{"name":"Salma K. Jabbour","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0171213817156222,"gpt":0.3587965159867576,"spread":0.3416751342711354,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001287054,0.001518886,0.002613038,0.0004457401,0.0004323759,0.0009461566,0.0007268192,0.00142959,0.006152942],"category_scores_gemma":[0.0007495861,0.0007270101,0.001774604,0.0004919473,0.001123642,0.0008381627,0.00045158,0.002854526,0.001587058],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005999717,"about_ca_system_score_gemma":0.001312343,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001275901,"about_ca_topic_score_gemma":0.002102684,"domain_scores_codex":[0.9994544,0.0002752892,0.00002978933,0.00008441006,0.00004592106,0.0001101608],"domain_scores_gemma":[0.9995984,0.00008633477,0.0000819579,0.00004125191,0.00003127631,0.0001607583],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9701005,0.008177365,0.0006173941,0.0005065232,0.0009348468,0.00002118925,0.00002853336,0.0003120239,0.004420928,0.0001138976,0.0008159895,0.01395093],"study_design_scores_gemma":[0.9238359,0.07288223,0.00129801,0.00001975152,0.0004668285,0.0000248974,0.00001340455,0.0002079985,0.0006108389,0.00007654631,0.0005543747,0.000009105487],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9859611,0.003829568,0.0009122223,0.0004523642,0.0004881366,0.003491119,0.00132577,0.0001555489,0.003384244],"genre_scores_gemma":[0.9817343,0.003961542,0.001695366,0.00120202,0.0003764976,0.003790722,0.001979108,0.00004810311,0.005212345],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006152942,"threshold_uncertainty_score":0.02058357,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4389488043","doi":"10.1016/j.iotech.2023.100537","title":"65O Phase III LEAP-008 study of lenvatinib plus pembrolizumab versus docetaxel for metastatic non-small cell lung cancer (NSCLC) that progressed on a PD-(L)1 inhibitor and platinum-containing chemotherapy","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pembrolizumab; Docetaxel; Medicine; Lenvatinib; Oncology; Chemotherapy; Internal medicine; Lung cancer; Phases of clinical research; Cancer; Immunotherapy","authors":[{"name":"Natasha B. Leighl","is_ca":true},{"name":"Luis Paz‐Ares","is_ca":false},{"name":"Delvys Rodríguez‐Abreu","is_ca":false},{"name":"Rina Hui","is_ca":false},{"name":"Sofia Baka","is_ca":false},{"name":"Frédéric Bigot","is_ca":false},{"name":"Makoto Nishio","is_ca":false},{"name":"Alexey Smolin","is_ca":false},{"name":"S. Ahmed","is_ca":false},{"name":"Adam J. Schoenfeld","is_ca":false},{"name":"S. Daher","is_ca":false},{"name":"Diego Cortinovis","is_ca":false},{"name":"V.P. Di Noia","is_ca":false},{"name":"Helena Linardou","is_ca":false},{"name":"Justin F. Gainor","is_ca":false},{"name":"Chinyere E. Okpara","is_ca":false},{"name":"Xuan Deng","is_ca":false},{"name":"Debra Kush","is_ca":false},{"name":"Andrew Song","is_ca":false},{"name":"Byoung Chul Cho","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04270142033337985,"gpt":0.3679328438520774,"spread":0.3252314235186975,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001293617,0.00154851,0.001992804,0.0005233922,0.0003968628,0.001709289,0.001331971,0.001502909,0.005763126],"category_scores_gemma":[0.0006890962,0.0007576459,0.001857969,0.0004309735,0.0009587822,0.0009368266,0.0004577366,0.004600973,0.001693649],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001729448,"about_ca_system_score_gemma":0.001989347,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003057545,"about_ca_topic_score_gemma":0.007348665,"domain_scores_codex":[0.9996768,0.0001333924,0.00001286283,0.00005271674,0.00003096464,0.00009321779],"domain_scores_gemma":[0.9995834,0.00005978423,0.0000521905,0.00002675058,0.00002623318,0.0002516031],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7706683,0.05692082,0.003842488,0.001329846,0.002876594,0.0002802814,0.0003385103,0.005300014,0.0317344,0.001039267,0.008220895,0.1174486],"study_design_scores_gemma":[0.704394,0.2760502,0.00712676,0.00006893422,0.0007473608,0.0002210988,0.00009743317,0.002485244,0.002680653,0.0004327917,0.00565104,0.00004461875],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9843313,0.00336001,0.0006551402,0.001000164,0.0004077831,0.002563345,0.002414806,0.0002055688,0.005061817],"genre_scores_gemma":[0.9733227,0.003466443,0.002179517,0.00170517,0.000211809,0.003542525,0.004483556,0.00006832887,0.01101995],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005763126,"threshold_uncertainty_score":0.01927954,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4405374502","doi":"10.1016/j.iotech.2024.101027","title":"LBA3 Perioperative pembrolizumab (pembro) plus neoadjuvant chemotherapy (chemo) in early-stage non-small-cell lung cancer (NSCLC): A 4-year update of KEYNOTE-671","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University","funders":"Chugai Pharmaceutical; EMD Serono; Berlin Institute of Health; Sun Pharma; Teijin Pharma; Medizinische Universität Innsbruck; Freie Universität Berlin; Hôpitaux Universitaires de Genève; Humboldt-Universität zu Berlin; Astellas Pharma; Eisai; Daiichi-Sankyo; Sanofi; Sungkyunkwan University; BeiGene; Mirati Therapeutics; University of Queensland; Helsinn; Les Laboratories Pierre Fabre; AstraZeneca; Novocure; Pfizer; Incyte; Universität Innsbruck; Merck KGaA; Taiho Pharmaceutical; Revolution Medicines; Regeneron Pharmaceuticals; Japan Surgical Society; Yuhan; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Amgen; Celgene; Eli Lilly and Company; Samsung; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Oncology; Stage (stratigraphy); Perioperative; Chemotherapy; Lung cancer; Internal medicine; Cancer; Radiology; Immunotherapy; Biology","authors":[{"name":"Margarita Majem","is_ca":false},{"name":"M.C. Garassino","is_ca":false},{"name":"G. Zhao","is_ca":false},{"name":"B. Mennecier","is_ca":false},{"name":"C. Grohe","is_ca":false},{"name":"Namiko Ikeda","is_ca":false},{"name":"J. Bosch-Barrera","is_ca":false},{"name":"Roger Keresztes","is_ca":false},{"name":"Yinjun Lou","is_ca":false},{"name":"H. Chen","is_ca":false},{"name":"Debasis Das","is_ca":false},{"name":"Sandra Keller","is_ca":false},{"name":"Ayman Samkari","is_ca":false},{"name":"Jonathan Spicer","is_ca":true},{"name":"H. Wakelee","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.008401937325614091,"gpt":0.2975276717874244,"spread":0.2891257344618103,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002737227,0.0005462312,0.001503532,0.001078829,0.0002286089,0.001318948,0.001034491,0.0009670343,0.003834896],"category_scores_gemma":[0.003575833,0.0002924694,0.001459532,0.001042192,0.0003187818,0.001490877,0.0007413438,0.003003652,0.001451439],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001347079,"about_ca_system_score_gemma":0.00171213,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001281668,"about_ca_topic_score_gemma":0.005136123,"domain_scores_codex":[0.9993716,0.0001397504,0.0001485214,0.00006242382,0.0001852745,0.00009247824],"domain_scores_gemma":[0.9979778,0.0009352464,0.0004028383,0.00006043402,0.0004702925,0.0001534465],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.001430063,0.0001315958,0.000895388,0.005622956,0.0003844807,0.0001103372,0.00004346621,0.0003352713,0.0019764,0.0008640785,0.0423771,0.9458289],"study_design_scores_gemma":[0.00201872,0.002512673,0.008560107,0.01138935,0.002917128,0.001384674,0.00008400313,0.0007298266,0.002840549,0.001899066,0.9655876,0.0000761807],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.005415077,0.9750404,0.0009281535,0.006647951,0.003241121,0.0001091355,0.0006602393,0.00008561202,0.007872289],"genre_scores_gemma":[0.03009553,0.9433768,0.003284345,0.01326908,0.003676728,0.0002254525,0.002102233,0.00006164375,0.003908273],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.003834896,"threshold_uncertainty_score":0.014476,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4401502464","doi":"10.1016/j.iotech.2024.100726","title":"Durable complete response after combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus (TILT-123) in a patient with metastatic mucosal melanoma","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Alethia Biotherapeutics (Canada)","funders":"Sigrid Juséliuksen Säätiö; Jane ja Aatos Erkon Säätiö; European Commission; Helsingin Yliopisto; Les Laboratories Pierre Fabre; Syöpäsäätiö; Novo Nordisk; Sanofi","keywords":"Oncolytic adenovirus; Oncolytic virus; Metastatic melanoma; Melanoma; Mucosal melanoma; Medicine; Tilt (camera); Cancer research; Tumor cells","authors":[{"name":"Tine Monberg","is_ca":false},{"name":"Tatiana V. Kudling","is_ca":false},{"name":"Benedetta Albieri","is_ca":false},{"name":"Santeri A. Pakola","is_ca":false},{"name":"Eva Ellebæk","is_ca":false},{"name":"Marco Donia","is_ca":false},{"name":"Rikke Løvendahl Eefsen","is_ca":false},{"name":"Christian von Buchwald","is_ca":false},{"name":"Claudia Kistler","is_ca":true},{"name":"João M. Santos","is_ca":true},{"name":"James H.A. Clubb","is_ca":true},{"name":"L. Haybout","is_ca":true},{"name":"Marie Christine Wulff Westergaard","is_ca":false},{"name":"Dafne C.A. Quixabeira","is_ca":true},{"name":"Elise Jirovec","is_ca":false},{"name":"Riikka Havunen","is_ca":true},{"name":"S. Sorsa","is_ca":true},{"name":"Víctor Cervera-Carrascón","is_ca":true},{"name":"A. Hemminki","is_ca":true},{"name":"Inge Marie Svane","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01077100026985764,"gpt":0.2736602485286825,"spread":0.2628892482588249,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001573765,0.0005034637,0.000667304,0.0003419353,0.0006634456,0.0003609644,0.0003152764,0.001575996,0.0008328556],"category_scores_gemma":[0.0004731655,0.0002634819,0.000470692,0.0002101993,0.0003694639,0.0002903941,0.0002971859,0.001019287,0.0002965047],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005285416,"about_ca_system_score_gemma":0.0002893313,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009507436,"about_ca_topic_score_gemma":0.001342894,"domain_scores_codex":[0.9998981,0.00001145299,0.000009347921,0.00002834689,0.0000151683,0.00003766792],"domain_scores_gemma":[0.9998124,0.00003881763,0.00002421348,0.00001774805,0.00001139737,0.00009541395],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"case_report","study_design_gemma":"case_report","study_design_scores_codex":[0.001088894,0.0002956748,0.02362819,0.0001204225,0.00005113625,0.9135755,0.0003727131,0.0004895615,0.04371971,0.0002806265,0.0005775425,0.0158001],"study_design_scores_gemma":[0.0001328135,0.002770647,0.03093535,0.00002432059,0.00009877336,0.9472446,0.0001348696,0.002298098,0.0138475,0.000194315,0.002289439,0.00002926149],"study_design_candidate":"case_report","study_design_consensus":"case_report","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9917191,0.001745647,0.001898458,0.001186522,0.00007608038,0.00007634421,0.0001307496,0.000116183,0.003050789],"genre_scores_gemma":[0.9978472,0.0003926342,0.0006276901,0.0002427546,0.00005136638,0.00001191098,0.00008317533,0.00001168915,0.0007316125],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001575996,"threshold_uncertainty_score":0.003834903,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4389480683","doi":"10.1016/j.iotech.2023.100693","title":"LBA3 Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in first-line (1L) metastatic NSCLC (mNSCLC): 5-year (y) overall survival (OS) update from the POSEIDON study","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"Medicine; Internal medicine; Durvalumab; Regimen; Chemotherapy; Gastroenterology; Progression-free survival; Nuclear medicine; Confidence interval; Oncology; Immunotherapy; Pembrolizumab; Cancer","authors":[{"name":"Solange Peters","is_ca":false},{"name":"Byoung Chul Cho","is_ca":false},{"name":"Alexander Luft","is_ca":false},{"name":"J.A. Alatorre Alexander","is_ca":false},{"name":"Sarayut Lucien Geater","is_ca":false},{"name":"К. К. Лактионов","is_ca":false},{"name":"Dmytro Trukhin","is_ca":false},{"name":"Seung‐Whan Kim","is_ca":false},{"name":"G. Ursol","is_ca":false},{"name":"Maen Hussein","is_ca":false},{"name":"F. Lim","is_ca":false},{"name":"Cheng‐Ta Yang","is_ca":false},{"name":"L.H. Araujo","is_ca":false},{"name":"H. Saito","is_ca":false},{"name":"Niels Reinmuth","is_ca":false},{"name":"Leah Szadkowski","is_ca":true},{"name":"C. Lowery","is_ca":false},{"name":"Edward B. Garon","is_ca":false},{"name":"Tony Mok","is_ca":false},{"name":"Melissa L. Johnson","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02537940517961945,"gpt":0.3139009496148696,"spread":0.2885215444352501,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001255378,0.0003150501,0.001119243,0.0001642503,0.0001708744,0.0005096843,0.0003566152,0.0002784719,0.001578027],"category_scores_gemma":[0.0003748274,0.0001349875,0.0007868928,0.0002306888,0.0002430963,0.0003210011,0.000192306,0.0009757046,0.0003777112],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005324554,"about_ca_system_score_gemma":0.0005078425,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008838241,"about_ca_topic_score_gemma":0.004103782,"domain_scores_codex":[0.9997926,0.00009551337,0.00001574337,0.00002781072,0.00003014202,0.00003813671],"domain_scores_gemma":[0.9997732,0.00005363866,0.00005836292,0.00001846069,0.00001379087,0.00008251688],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3847532,0.01154543,0.02632907,0.001340739,0.001714422,0.0002097416,0.000243017,0.003051684,0.05329271,0.0004707024,0.007227376,0.509822],"study_design_scores_gemma":[0.2162602,0.5587295,0.164274,0.0002677503,0.003681558,0.001472297,0.0001940245,0.004627146,0.0242611,0.0009715703,0.02516835,0.00009255346],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9886491,0.007974375,0.0003731019,0.0002521055,0.00007408841,0.0002426582,0.0008899636,0.00005303335,0.001491487],"genre_scores_gemma":[0.9918529,0.00401554,0.0007131403,0.0003692955,0.00005560808,0.0002583734,0.001496416,0.00001613236,0.001222648],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001578027,"threshold_uncertainty_score":0.006639183,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4389480868","doi":"10.1016/j.iotech.2023.100606","title":"134P A phase I study exploring the safety and tolerability of the small molecule PD-L1 inhibitor INCB099318 in select advanced solid tumors","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Chugai Pharmaceutical; Incyte; Sierra Oncology; Da Volterra; Ipsen; Eisai; Bristol-Myers Squibb; AstraZeneca; Carrick Therapeutics; Pfizer; Dr. Falk Pharma; ViiV Healthcare","keywords":"Tolerability; Medicine; Pharmacokinetics; Internal medicine; Adverse effect; Clinical endpoint; Gastroenterology; Oncology; Pharmacology; Clinical trial","authors":[{"name":"David J. Pinato","is_ca":false},{"name":"Udai Banerji","is_ca":false},{"name":"Sylvie Rottey","is_ca":false},{"name":"Katriina Peltola","is_ca":false},{"name":"Jeffrey Yachnin","is_ca":false},{"name":"Rebecca Kristeleit","is_ca":false},{"name":"Martin Gutierrez","is_ca":false},{"name":"Stefan N. Symeonides","is_ca":false},{"name":"Nina Louise Jebsen","is_ca":false},{"name":"M. Hoejgaard","is_ca":false},{"name":"William J. Edenfield","is_ca":false},{"name":"Knut B. Smeland","is_ca":false},{"name":"Aglaia Schiza","is_ca":false},{"name":"Lars Ny","is_ca":false},{"name":"V. Ebiana","is_ca":false},{"name":"Jeannie Daniel","is_ca":false},{"name":"Jennifer Pulini","is_ca":false},{"name":"Ruth Plummer","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04229348806635307,"gpt":0.3719076108827646,"spread":0.3296141228164115,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006272413,0.0004082361,0.0005784148,0.0002503366,0.0002435471,0.000418423,0.0003570127,0.000406785,0.008786066],"category_scores_gemma":[0.0006203933,0.0001326791,0.0007070694,0.0003212448,0.0001979104,0.0002500825,0.0001994739,0.00151195,0.001363833],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005537936,"about_ca_system_score_gemma":0.0009629517,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001248436,"about_ca_topic_score_gemma":0.002594083,"domain_scores_codex":[0.9998196,0.00007009254,0.00001011373,0.00002851872,0.00004118709,0.00003052369],"domain_scores_gemma":[0.9997085,0.00007501457,0.00005086889,0.0000226128,0.00004576483,0.00009722596],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2135749,0.02833087,0.02167068,0.001738236,0.001718266,0.0009731019,0.0001350057,0.004382869,0.1334693,0.0009534284,0.07848437,0.514569],"study_design_scores_gemma":[0.2414443,0.4958096,0.1070449,0.0001997891,0.001598189,0.003049563,0.0001039547,0.004920234,0.05225696,0.001142077,0.09233873,0.00009160762],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9301314,0.003341478,0.004019354,0.002016396,0.0002203121,0.005933326,0.03418713,0.0004515289,0.01969898],"genre_scores_gemma":[0.9247515,0.00356502,0.007263955,0.00236296,0.0001563601,0.004462042,0.04215483,0.0001185568,0.01516485],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008786066,"threshold_uncertainty_score":0.0293923,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4405375144","doi":"10.1016/j.iotech.2024.100750","title":"121MO Anti-IL-8 (BMS-986253) in combination with nivolumab (NIVO) plus ipilimumab (IPI) in patients (pts) with advanced melanoma: Final analysis from the randomized part 2 of the phase I/II CA027-002 study","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"Genentech; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung; PharmaMar; European Society for Medical Oncology","keywords":"Nivolumab; Ipilimumab; Medicine; Metastatic melanoma; Internal medicine; Melanoma; Oncology; Cancer research; Immunotherapy; Cancer","authors":[{"name":"Matteo Simonelli","is_ca":false},{"name":"M.O. Butler","is_ca":true},{"name":"P.A. Ascierto","is_ca":false},{"name":"G.V. Long","is_ca":false},{"name":"E. Calvo","is_ca":false},{"name":"C. Gebhardt","is_ca":false},{"name":"J.J. Grob","is_ca":false},{"name":"A.M. Haydon","is_ca":false},{"name":"G. Quéreux","is_ca":false},{"name":"J. Walker","is_ca":false},{"name":"Manoj Kumar","is_ca":false},{"name":"D. Chakraborty","is_ca":false},{"name":"Xu Zhu","is_ca":false},{"name":"Ignacio Melero","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.008657859952414042,"gpt":0.2774406519264998,"spread":0.2687827919740858,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001017731,0.0005088613,0.000930234,0.0002403494,0.0001847662,0.0005018871,0.0003225921,0.000441163,0.001985405],"category_scores_gemma":[0.0006497307,0.0003089764,0.0008249753,0.0002490696,0.0002756896,0.0003352673,0.0002259801,0.001113414,0.0003939196],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004716797,"about_ca_system_score_gemma":0.0005680472,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006287582,"about_ca_topic_score_gemma":0.002133267,"domain_scores_codex":[0.999685,0.0001828504,0.00001569677,0.00003700365,0.00003411841,0.00004532568],"domain_scores_gemma":[0.9997094,0.0000655184,0.00006897622,0.00002118095,0.00002009719,0.0001147271],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7574698,0.01671321,0.02129646,0.0009462241,0.003184005,0.000177556,0.0001664725,0.002097182,0.03708604,0.0001447688,0.002903668,0.1578147],"study_design_scores_gemma":[0.4336295,0.4730378,0.07618814,0.0000819798,0.002513566,0.0003060519,0.00007179294,0.00229794,0.007187608,0.0001756916,0.004478048,0.0000318862],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9965566,0.001806687,0.0001441797,0.0001861067,0.00004357412,0.0003340086,0.0002441846,0.00002592486,0.0006587188],"genre_scores_gemma":[0.9967138,0.0009977483,0.0004077006,0.0001874823,0.0000687854,0.0002915883,0.0004967999,0.000005926735,0.00083023],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001985405,"threshold_uncertainty_score":0.006641805,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4389487695","doi":"10.1016/j.iotech.2023.100587","title":"115TiP MDT-BRIDGE: A phase II study of neoadjuvant durvalumab (D) + chemotherapy (CT) followed by either surgery and adjuvant D or chemoradiotherapy (CRT) and consolidation D in patients (pts) with resectable or borderline resectable stage IIB–IIIB NSCLC","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Medical Imaging Techniques and Applications","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University","funders":"Genentech; LEO Pharma; Aptitude Health; European Society for Medical Oncology; Novocure; Regeneron Pharmaceuticals; Gilead Sciences; Ipsen; BeiGene; Daiichi Sankyo Europe; Sanofi; Amgen; Pfizer; Les Laboratories Pierre Fabre; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Neoadjuvant therapy; Internal medicine; Durvalumab; Oncology; Stage (stratigraphy); Chemotherapy; Radiology; Cancer; Immunotherapy; Pembrolizumab","authors":[{"name":"Martin Reck","is_ca":false},{"name":"Ernest Nadal","is_ca":false},{"name":"Nicolas Girard","is_ca":false},{"name":"A.R.R. Filippi","is_ca":false},{"name":"L.W. Martin","is_ca":false},{"name":"C.M. Gay","is_ca":false},{"name":"Cordula Petersen","is_ca":false},{"name":"Daniel P. Gale","is_ca":false},{"name":"H.R. Bridge","is_ca":false},{"name":"Naomi Donner","is_ca":false},{"name":"N.E. Georgoulia","is_ca":false},{"name":"Jonathan Spicer","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02619642708077443,"gpt":0.3546546211225938,"spread":0.3284581940418194,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001076866,0.001093356,0.001458701,0.0002416092,0.0002978801,0.0009068616,0.0008899892,0.001143244,0.005949538],"category_scores_gemma":[0.0007055253,0.0004299693,0.001204845,0.0003096747,0.0005743215,0.0006330829,0.0003763357,0.003061536,0.001515495],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008231794,"about_ca_system_score_gemma":0.001336635,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001082337,"about_ca_topic_score_gemma":0.003322117,"domain_scores_codex":[0.9997726,0.0001038424,0.00001381986,0.00003820693,0.00002846907,0.00004306423],"domain_scores_gemma":[0.9996107,0.00006229506,0.00006416155,0.00003077013,0.0000271414,0.000204973],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6750806,0.07992527,0.007340947,0.00262788,0.002647218,0.0002475338,0.0003502402,0.002449418,0.0535505,0.0007824117,0.01244877,0.1625492],"study_design_scores_gemma":[0.6888365,0.2920952,0.00894609,0.00008653342,0.0005804518,0.0001973136,0.00006247302,0.0009713709,0.002565845,0.0002261469,0.005400292,0.00003170048],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9775698,0.003707032,0.0009319441,0.001061597,0.0003879824,0.005877826,0.003876716,0.0002311879,0.006355882],"genre_scores_gemma":[0.9623253,0.004488101,0.004147479,0.003390411,0.0002900248,0.00700835,0.009732023,0.00007699739,0.008541374],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005949538,"threshold_uncertainty_score":0.01990312,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4389480655","doi":"10.1016/j.iotech.2023.100692","title":"LBA2 First-line (1L) durvalumab (D) + platinum-etoposide (EP) for patients (pts) with extensive-stage SCLC (ES-SCLC): Primary results from the phase IIIb LUMINANCE study","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"Symphogen; Astellas Pharma; Gilead Sciences; Daiichi-Sankyo; Amgen; Pfizer; AstraZeneca; Daiichi Sankyo Europe; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Durvalumab; Internal medicine; Neutropenia; Gastroenterology; Etoposide; Cancer; Chemotherapy; Immunotherapy; Pembrolizumab","authors":[{"name":"Niels Reinmuth","is_ca":false},{"name":"Mustafa Özgüroğlu","is_ca":false},{"name":"Natasha B. Leighl","is_ca":true},{"name":"Domenico Galetta","is_ca":false},{"name":"İlhan Hacıbekiroğlu","is_ca":false},{"name":"Jaromı́r Roubec","is_ca":false},{"name":"Mehmet Alı Nahıt Şendur","is_ca":false},{"name":"Emilio Bria","is_ca":false},{"name":"Christian Grohé","is_ca":false},{"name":"Hakan Harputluoğlu","is_ca":false},{"name":"Saadettin Kılıçkap","is_ca":false},{"name":"Silvia Novello","is_ca":false},{"name":"Petr Opálka","is_ca":false},{"name":"Ferdinando Riccardi","is_ca":false},{"name":"Rossitza Krasteva Ruseva","is_ca":false},{"name":"Susanne Lang","is_ca":false},{"name":"Moana Hodari","is_ca":false},{"name":"Naomi Donner","is_ca":false},{"name":"Filippo de Marinis","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03270754885638696,"gpt":0.3655740603058458,"spread":0.3328665114494589,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008755853,0.0002823187,0.000828456,0.0002259996,0.000157764,0.0005847388,0.0004086864,0.000280828,0.003050161],"category_scores_gemma":[0.0005554331,0.000165381,0.0005352491,0.0002516182,0.0002190054,0.000389199,0.0001855862,0.0009520729,0.0006350526],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007893299,"about_ca_system_score_gemma":0.0006569457,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001194951,"about_ca_topic_score_gemma":0.00584434,"domain_scores_codex":[0.9997864,0.0001075469,0.0000103084,0.00002986164,0.0000316668,0.00003422737],"domain_scores_gemma":[0.9997826,0.00003759245,0.0000554829,0.00002097231,0.0000150462,0.00008828175],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3677121,0.01702302,0.05628551,0.001767375,0.002113811,0.0003782281,0.0002721225,0.005351107,0.04696689,0.0005971396,0.02348013,0.4780526],"study_design_scores_gemma":[0.3400664,0.390466,0.2007678,0.0003013269,0.002802701,0.001976311,0.0002839977,0.00888904,0.01853353,0.0008029413,0.03502852,0.00008148329],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9860048,0.005467269,0.0004981833,0.0003668822,0.0000609735,0.000621688,0.002673457,0.0001468029,0.004160047],"genre_scores_gemma":[0.9900934,0.001651042,0.0007990863,0.000477647,0.00004470636,0.000386032,0.004104325,0.00002472451,0.002419042],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003050161,"threshold_uncertainty_score":0.01020378,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4311139822","doi":"10.1016/j.iotech.2022.100303","title":"191P Preliminary biomarker and safety results of SQZ-PBMC-HPV at RP2D in monotherapy and combination with checkpoint inhibitors in HLA A*02+ patients with recurrent, locally advanced, or metastatic HPV16+ solid tumors","year":2022,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Internal medicine; Oncology; Pharmacodynamics; Immunotherapy; Peripheral blood mononuclear cell; Cancer; Antigen; Immunology; Pharmacokinetics","authors":[{"name":"Antonio Jimeno","is_ca":false},{"name":"N.R. Miselis","is_ca":false},{"name":"J.C. Park","is_ca":false},{"name":"J. Jennings","is_ca":false},{"name":"N. Dhani","is_ca":true},{"name":"U. Holtick","is_ca":false},{"name":"W.T. Iams","is_ca":false},{"name":"K. Rodabaugh","is_ca":false},{"name":"N. Nair","is_ca":false},{"name":"M. Kornacker","is_ca":false},{"name":"S.M. Loughhead","is_ca":false},{"name":"H. Bernstein","is_ca":false},{"name":"R. Zwirtes","is_ca":false},{"name":"Ruqian Ji","is_ca":false},{"name":"M. Warren","is_ca":false},{"name":"Aiman Al Sharei","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.007143621557407641,"gpt":0.2751821166317269,"spread":0.2680384950743192,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007819706,0.0004418864,0.0008051628,0.0002926267,0.0001933431,0.0005359356,0.0001864393,0.0005235042,0.002606778],"category_scores_gemma":[0.0009479481,0.0001399883,0.0007038296,0.0002611844,0.0002640865,0.0003674331,0.0001475161,0.001120274,0.0005967239],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003993223,"about_ca_system_score_gemma":0.0003484519,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004153785,"about_ca_topic_score_gemma":0.0005981404,"domain_scores_codex":[0.9996327,0.0001140004,0.00002531857,0.00008138992,0.00008699863,0.00005958687],"domain_scores_gemma":[0.9993506,0.0002240973,0.0001251451,0.00006188076,0.0001095375,0.0001288067],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.136098,0.008276695,0.07803444,0.0007889768,0.001490855,0.002044616,0.0003976846,0.00455165,0.4535925,0.0004461666,0.006216309,0.308062],"study_design_scores_gemma":[0.009678215,0.4689907,0.1867783,0.0001140399,0.002858482,0.005660628,0.0002976678,0.007119543,0.2837333,0.000891157,0.0337625,0.000115374],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9837837,0.005418576,0.002359274,0.0007203835,0.0001530798,0.0003484391,0.001948676,0.0001599453,0.005108106],"genre_scores_gemma":[0.9924585,0.0008748559,0.0009008076,0.0003880188,0.00008518514,0.0001535438,0.002379373,0.00002369733,0.002736081],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002606778,"threshold_uncertainty_score":0.008720517,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4405374803","doi":"10.1016/j.iotech.2024.100791","title":"162P EO4010 (EO) + nivolumab (N) ± bevacizumab (B) in patients (pts) with microsatellite stable (MSS) metastatic colorectal carcinoma (mCRC)","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Cilag; Chugai Pharmaceutical; AstraZeneca; Genentech; Seagen; Institut Servier; INCLIVA Instituto de Investigación Sanitaria; Menarini Group; EMD Serono; Deutschen Konsortium für Translationale Krebsforschung; Sociedad Española de Oncología Médica; PharmaMar; Novartis Farmacéutica; Daiichi Sankyo Europe; European Society for Medical Oncology; Grifols; Fundación Científica Asociación Española Contra el Cáncer; Regeneron Pharmaceuticals; Natera; BeiGene; Les Laboratories Pierre Fabre; Exelixis; Revolution Medicines; Cancer Research UK; Ribon Therapeutics; Takeda Pharmaceuticals International; Array BioPharma; Gilead Sciences; Taiho Pharmaceutical; F. Hoffmann-La Roche; HORIZON EUROPE Framework Programme; Servier; Astellas Pharma; Samsung; Eisai; FibroGen; Bristol-Myers Squibb; Eli Lilly and Company; Institut National Du Cancer; Oncode Institute; American Society of Clinical Oncology; Foundation Medicine; Sierra Oncology; European Association for Cancer Research; Sanofi; Amgen; Pfizer; Celgene","keywords":"Bevacizumab; Nivolumab; Colorectal cancer; Medicine; Oncology; Internal medicine; Metastatic melanoma; Cancer research; Chemotherapy; Immunotherapy; Cancer","authors":[{"name":"R. Cohen","is_ca":false},{"name":"M.E. Elez Fernandez","is_ca":false},{"name":"N. Tarazona Llavero","is_ca":false},{"name":"N.A. Dasari","is_ca":false},{"name":"T. Mazard","is_ca":false},{"name":"C. Borg","is_ca":false},{"name":"Hélène Toussaint","is_ca":false},{"name":"Lucie Aubergeon","is_ca":false},{"name":"L. Chêne","is_ca":false},{"name":"Svetlana Balandraud","is_ca":false},{"name":"J. Fagerberg","is_ca":false},{"name":"H.J.E-V. Schmoll","is_ca":false},{"name":"Andrés Cervantes","is_ca":false},{"name":"S. Kopetz","is_ca":false},{"name":"J. Tabernero","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.008630389719972233,"gpt":0.2672043473917885,"spread":0.2585739576718163,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003947846,0.0002297011,0.0005769889,0.0001234628,0.000147627,0.0003066273,0.0001233999,0.0003210213,0.001566908],"category_scores_gemma":[0.0006612017,0.0001355683,0.000469835,0.0001948313,0.0001434159,0.0003400524,0.0001645006,0.0006619078,0.0001896326],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003215104,"about_ca_system_score_gemma":0.0005084988,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001003626,"about_ca_topic_score_gemma":0.003157464,"domain_scores_codex":[0.9998679,0.00004903594,0.00001038608,0.00002599222,0.00001390216,0.00003274501],"domain_scores_gemma":[0.9998267,0.00004153461,0.00003372479,0.00000613019,0.000009430768,0.00008252216],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6073079,0.006694918,0.154961,0.0009012391,0.001417384,0.0008311414,0.0002000014,0.001696397,0.01626725,0.0002800605,0.003291488,0.2061512],"study_design_scores_gemma":[0.05777522,0.3429145,0.5718543,0.0003339516,0.003385122,0.001577719,0.0004180889,0.003500742,0.004169622,0.0005625186,0.01345652,0.00005171862],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9954596,0.002681089,0.00008095397,0.0002006925,0.0000834859,0.00006045891,0.000119724,0.000008097578,0.001305787],"genre_scores_gemma":[0.9978865,0.0009171746,0.0001501503,0.0001412237,0.00005003075,0.00004069442,0.0001702241,0.000001651589,0.0006423782],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001566908,"threshold_uncertainty_score":0.005241871,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4405374533","doi":"10.1016/j.iotech.2024.100886","title":"2O TILs and PD-L1 early dynamics in the randomized Neo-CheckRay phase II trial evaluating neo-adjuvant immuno-radiation and adenosine pathway blockade for early-stage, high risk ER+/HER2- breast cancer (BC)","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal","funders":"Japanese Respiratory Society; Japan Agency for Medical Research and Development","keywords":"Adenosine; Adjuvant; Blockade; Oncology; Stage (stratigraphy); Medicine; Internal medicine; Breast cancer; Randomized controlled trial; Receptor; Biology; Cancer","authors":[{"name":"A. De Caluwé","is_ca":false},{"name":"Xavier Catteau","is_ca":false},{"name":"Zoë Denis","is_ca":false},{"name":"Marcela Carausu","is_ca":false},{"name":"Isabelle Desmoulins","is_ca":false},{"name":"Emanuela Romano","is_ca":false},{"name":"Vincent Remouchamps","is_ca":false},{"name":"A. Baten","is_ca":false},{"name":"P. Poortmans","is_ca":false},{"name":"Cédric van Marcke","is_ca":false},{"name":"F. Rothé","is_ca":false},{"name":"Michail Ignatiadis","is_ca":false},{"name":"Martine Piccart","is_ca":false},{"name":"Denis Larsimont","is_ca":false},{"name":"John Stagg","is_ca":true},{"name":"Christos Sotiriou","is_ca":false},{"name":"Roberto Salgado","is_ca":false},{"name":"Laurence Buisseret","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01471683082262123,"gpt":0.3441883121831741,"spread":0.3294714813605529,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006900099,0.0004693992,0.0009818691,0.0001827844,0.0002248599,0.0009340041,0.0004042047,0.000752826,0.005655898],"category_scores_gemma":[0.0008650804,0.0002231639,0.0006993776,0.0001533327,0.0003604362,0.0005071435,0.0003343398,0.001765339,0.0005595786],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006192671,"about_ca_system_score_gemma":0.0005897122,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005783235,"about_ca_topic_score_gemma":0.001476721,"domain_scores_codex":[0.9997825,0.0000919526,0.00001028395,0.0000476069,0.00002155965,0.00004618485],"domain_scores_gemma":[0.9996113,0.0000872918,0.00008484835,0.00003156727,0.00002735418,0.0001576504],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8995577,0.009143846,0.007157859,0.0004269327,0.000693323,0.00004490071,0.00007636149,0.00100655,0.009483979,0.0002623056,0.003319177,0.06882714],"study_design_scores_gemma":[0.6445383,0.3024023,0.03605192,0.0001338287,0.001343143,0.000189514,0.0001063707,0.003111216,0.004641319,0.001021989,0.006424352,0.00003571014],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9937657,0.002002634,0.0002511731,0.000553384,0.0001596014,0.0005272433,0.0007420071,0.00006708909,0.001931123],"genre_scores_gemma":[0.9929863,0.0004798821,0.0005673871,0.0007558672,0.0000951246,0.000760279,0.001405545,0.00001614893,0.002933393],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005655898,"threshold_uncertainty_score":0.01892084,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4405374985","doi":"10.1016/j.iotech.2024.100845","title":"102P A real-world study of the efficacy of second-line treatment of unresectable hepatocellular carcinoma after progression on first-line lenvatinib combined with PD-1 inhibitor","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Lenvatinib; Hepatocellular carcinoma; Medicine; Oncology; Internal medicine; Second line; Line (geometry); First line; Sorafenib","authors":[{"name":"S. Li","is_ca":false},{"name":"Qi Wen","is_ca":false},{"name":"Wen‐Tsung Huang","is_ca":false},{"name":"Long Feng","is_ca":false},{"name":"Yi Fan","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03585710363949379,"gpt":0.2980887263409522,"spread":0.2622316227014584,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01377752,0.001078138,0.005956038,0.002700443,0.0004753797,0.002295091,0.001022045,0.002142434,0.006705258],"category_scores_gemma":[0.04118028,0.0007225588,0.01770582,0.003806879,0.0007394961,0.001659617,0.001106472,0.001920259,0.0006352427],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001796025,"about_ca_system_score_gemma":0.002167232,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002308175,"about_ca_topic_score_gemma":0.00314002,"domain_scores_codex":[0.9860486,0.007593296,0.003424705,0.001400814,0.001178375,0.0003542123],"domain_scores_gemma":[0.9629764,0.02169759,0.01095594,0.001304279,0.002410021,0.0006556943],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"observational","study_design_scores_codex":[0.1379711,0.0009853693,0.04494952,0.2312033,0.5444107,0.0006760793,0.0003685135,0.0008716004,0.00101668,0.0004347085,0.00207144,0.03504097],"study_design_scores_gemma":[0.05439051,0.0168176,0.08578052,0.03332939,0.7956727,0.00091216,0.0004524764,0.0009841886,0.0007580036,0.0005536315,0.01018945,0.0001594019],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.2868854,0.6929647,0.001534403,0.001602886,0.0007403679,0.003055639,0.009244036,0.00007692945,0.003895596],"genre_scores_gemma":[0.9467521,0.04642078,0.001315534,0.0009467895,0.0003273381,0.00146398,0.002139227,0.00002348996,0.0006108296],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.01377752,"threshold_uncertainty_score":0.0728634,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4389480748","doi":"10.1016/j.iotech.2023.100601","title":"129P Naxitamab efficacy in patients with refractory/relapsed high-risk neuroblastoma and bone metastases as assessed by Curie score","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Neuroblastoma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Refractory (planetary science); Neuroblastoma; Internal medicine; Population; Bone marrow; Phases of clinical research; Interim analysis; Oncology; Nuclear medicine; Gastroenterology; Clinical trial","authors":[{"name":"Brian H. Kushner","is_ca":false},{"name":"Jaume Mora","is_ca":false},{"name":"Gcf Chan","is_ca":false},{"name":"Daniel A. Morgenstern","is_ca":true},{"name":"Loredana Amoroso","is_ca":false},{"name":"K. Nysom","is_ca":false},{"name":"Joerg Faber","is_ca":false},{"name":"Arthur Wingerter","is_ca":false},{"name":"Melissa Bear","is_ca":false},{"name":"M. During","is_ca":false},{"name":"Karen Tornøe","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.007183636098152099,"gpt":0.2752357812312524,"spread":0.2680521451331003,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001507088,0.0002786971,0.001531993,0.0003711504,0.0001656923,0.0003958662,0.0002089616,0.0002507817,0.0008469316],"category_scores_gemma":[0.0009169111,0.0001149997,0.000609772,0.0003179356,0.0001995666,0.0003273464,0.0002707604,0.0005193892,0.0002196449],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000493178,"about_ca_system_score_gemma":0.000510525,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008236058,"about_ca_topic_score_gemma":0.002876317,"domain_scores_codex":[0.9995738,0.0001838131,0.00003987923,0.00005306625,0.00008116964,0.00006825294],"domain_scores_gemma":[0.9995135,0.0001483991,0.0001330746,0.00003320813,0.00004433867,0.0001274554],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.2345595,0.003571974,0.5002889,0.0009680185,0.002514452,0.001330546,0.0003926065,0.005076267,0.07894098,0.0002893141,0.004211165,0.1678564],"study_design_scores_gemma":[0.01317896,0.106978,0.8623392,0.000065412,0.001005665,0.001373972,0.0001110018,0.002749111,0.006267108,0.0002728288,0.005615346,0.00004340097],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9959177,0.001526387,0.0001457493,0.00006712149,0.000010644,0.0001871,0.0006323317,0.00001823314,0.001494589],"genre_scores_gemma":[0.9965922,0.0004973795,0.0003435736,0.0001110626,0.0000205798,0.0001918469,0.001695426,0.000006314394,0.0005417263],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001531993,"threshold_uncertainty_score":0.007970333,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W7117306841","doi":"10.1016/j.iotech.2025.101399","title":"402P TMEM33 loss enhances CD8+ T cell functionality and tumour control","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Discovery Centre","funders":"","keywords":"T cell; Cytotoxic T cell; Immune system; T lymphocyte; Cell","authors":[{"name":"M.T. Jackson","is_ca":false},{"name":"T. Zhao","is_ca":false},{"name":"G.B. Milotay","is_ca":false},{"name":"I. Pedroza-Pacheco","is_ca":false},{"name":"A. Grover","is_ca":false},{"name":"D. Gabrilovich","is_ca":false},{"name":"J. Rehwinkel","is_ca":true},{"name":"B.P. Fairfax","is_ca":false},{"name":"E. Honoré","is_ca":false},{"name":"D. Withers","is_ca":false},{"name":"E.E. Parkes","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.006170921108255087,"gpt":0.2813748800299773,"spread":0.2752039589217223,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001086282,0.0002751637,0.0001661279,0.0001162786,0.0001406294,0.0003039183,0.0001517086,0.0004712734,0.004083157],"category_scores_gemma":[0.0001199625,0.0001213775,0.0001629832,0.0001153877,0.000248883,0.0002442468,0.0002097095,0.001007348,0.0008561572],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002355399,"about_ca_system_score_gemma":0.0001728337,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000459873,"about_ca_topic_score_gemma":0.0003852988,"domain_scores_codex":[0.9998268,0.00003323356,0.000008925296,0.00002342992,0.00003790126,0.0000697126],"domain_scores_gemma":[0.9999396,0.00001420102,0.0000151219,0.000009351475,0.00000479807,0.00001703385],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0002552604,0.00005181343,0.0001058008,0.00001948314,0.000003698003,0.00006685885,0.00001327794,0.0001469853,0.9977115,0.0001857968,0.0001276726,0.001311853],"study_design_scores_gemma":[0.00004149853,0.0004428173,0.002287732,0.000004511147,0.00001124097,0.0003682855,0.00004197201,0.001372363,0.9907267,0.0001027263,0.004595854,0.000004246257],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9961422,0.0003542968,0.001212697,0.0001492549,0.00003342626,0.0000200657,0.0002413791,0.00008519406,0.001761581],"genre_scores_gemma":[0.9963181,0.000130647,0.0004973994,0.00005171205,0.000004764071,0.00001669208,0.0002469963,0.00002002219,0.002713564],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004083157,"threshold_uncertainty_score":0.01365954,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W7117310539","doi":"10.1016/j.iotech.2025.101097","title":"12P Stromal CD73 expression in early-stage high-risk luminal B-like breast cancer: An exploratory analysis from the randomized Neo-CheckRay trial","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal","funders":"","keywords":"Stromal cell; Exploratory analysis; Adenosine; Breast cancer; Immune system; Pathological; Randomized controlled trial; Clinical trial","authors":[{"name":"Z. Denis","is_ca":false},{"name":"A. De Caluwe","is_ca":false},{"name":"E. Romano","is_ca":false},{"name":"J. Stagg","is_ca":true},{"name":"T. Yin","is_ca":false},{"name":"J. Dhont","is_ca":false},{"name":"F. Lifrange","is_ca":false},{"name":"M. Carausu","is_ca":false},{"name":"C. Sotiriou","is_ca":false},{"name":"L. Buisseret","is_ca":false},{"name":"X. Catteau","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.006197744301364331,"gpt":0.2698546813712414,"spread":0.263656937069877,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001029763,0.00035995,0.0006212513,0.0001374201,0.0001535409,0.000507705,0.0002418357,0.0003146974,0.001899588],"category_scores_gemma":[0.0009119123,0.000126699,0.0005699715,0.0002510666,0.0002890514,0.0002698725,0.0002314277,0.0005886764,0.0001928454],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002868049,"about_ca_system_score_gemma":0.0002771343,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002723571,"about_ca_topic_score_gemma":0.0007253858,"domain_scores_codex":[0.9996561,0.000190497,0.00001770829,0.00005374103,0.00003962282,0.00004239321],"domain_scores_gemma":[0.9993179,0.0002422905,0.0001857941,0.00007686955,0.00005099305,0.0001261143],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7341149,0.002432528,0.1886494,0.0006377233,0.002641021,0.0002781016,0.00009464449,0.000907338,0.01963802,0.0003918235,0.002241276,0.04797317],"study_design_scores_gemma":[0.139598,0.0870517,0.7451782,0.00009779834,0.006525022,0.001170525,0.0002226505,0.003114701,0.008869152,0.001026385,0.007082794,0.00006316227],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9974998,0.001040677,0.0001283018,0.0001039583,0.00001570491,0.00008977963,0.0006086023,0.000006651135,0.0005065078],"genre_scores_gemma":[0.9977891,0.0002447386,0.000210663,0.00009833226,0.00004781576,0.0001034686,0.00111825,0.000003105248,0.0003845731],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001899588,"threshold_uncertainty_score":0.006354809,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W7117316366","doi":"10.1016/j.iotech.2025.101405","title":"408P Calpain as a novel therapeutic target in breast cancer","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Calpain Protease Function and Regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Queen's University","funders":"","keywords":"Breast cancer; Calpain; Cancer; Human breast; Disease","authors":[{"name":"D. Harper","is_ca":true},{"name":"I. Shapovalov","is_ca":true},{"name":"J.Y. Min","is_ca":true},{"name":"B.J. Laight","is_ca":true},{"name":"S. Cockburn","is_ca":true},{"name":"A. Aaron","is_ca":true},{"name":"Y. Gao","is_ca":true},{"name":"P.A. Greer","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.004559655176082028,"gpt":0.2819368003166113,"spread":0.2773771451405293,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003091867,0.0004375738,0.0002482301,0.0003139958,0.00018827,0.0005058359,0.0003922212,0.000549102,0.00163398],"category_scores_gemma":[0.0001479074,0.0001593963,0.0002202102,0.0002618196,0.0002412618,0.0003696751,0.0002343198,0.0009425706,0.0005095153],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004914824,"about_ca_system_score_gemma":0.0002726112,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003525087,"about_ca_topic_score_gemma":0.0004500248,"domain_scores_codex":[0.9999261,0.00001305296,0.000003826332,0.00001325596,0.00002164367,0.00002211345],"domain_scores_gemma":[0.999965,0.000008017195,0.000006672057,0.000003488007,0.000007708584,0.000009062452],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0007147091,0.0002911918,0.0003726002,0.0003080418,0.0000207684,0.0006053432,0.00004825358,0.0004548423,0.9325353,0.003213174,0.001460043,0.05997572],"study_design_scores_gemma":[0.0004026247,0.002317038,0.003024705,0.00004857301,0.00008728938,0.003189089,0.00005077593,0.002604443,0.9240274,0.00176689,0.06246589,0.00001538976],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7651346,0.1646261,0.03051745,0.006879079,0.001075534,0.0002970358,0.0005723991,0.0006301341,0.03026766],"genre_scores_gemma":[0.9348155,0.04097831,0.01008916,0.0007465543,0.0002996377,0.0001308543,0.0004665206,0.00004731467,0.01242606],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00163398,"threshold_uncertainty_score":0.005466163,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W7117307022","doi":"10.1016/j.iotech.2025.101348","title":"351P Association of G-coupled protein receptor 65 (GPR65), a novel therapeutic target, with immune cell subsets in metastatic renal cell carcinoma (mRCC)","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"MD Precision (Canada)","funders":"","keywords":"Renal cell carcinoma; Immune system; Kidney cancer; Receptor; Cell; Immunotherapy; T cell; Kidney","authors":[{"name":"K. Shah","is_ca":false},{"name":"N.J. Salgia","is_ca":false},{"name":"S.V. Ambarkhane","is_ca":false},{"name":"B. Cipriani","is_ca":false},{"name":"D. Memon","is_ca":true},{"name":"M.J. Oliva Martin","is_ca":false},{"name":"M. Zugman","is_ca":false},{"name":"S. Jaime-Casas","is_ca":false},{"name":"P. Zang","is_ca":false},{"name":"V. Abreu de Goes","is_ca":false},{"name":"J. Hsu","is_ca":false},{"name":"S.K. Pal","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.009426331137015345,"gpt":0.2507016620731092,"spread":0.2412753309360939,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001440817,0.000167826,0.0002071949,0.0001041617,0.0001590256,0.0002538215,0.0001291063,0.0002690232,0.002064836],"category_scores_gemma":[0.0001212999,0.00008877632,0.0002394616,0.0001149489,0.0001410921,0.0001646101,0.0002654959,0.0003639792,0.000387168],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002160384,"about_ca_system_score_gemma":0.0001899015,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006265264,"about_ca_topic_score_gemma":0.0006600189,"domain_scores_codex":[0.9999005,0.0000173003,0.000004054426,0.00001747534,0.00001900251,0.00004180147],"domain_scores_gemma":[0.9999806,0.000003205976,0.000004846038,0.000001909016,0.000002281622,0.000007186571],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.0009820297,0.00009864671,0.001428905,0.000165542,0.00003588414,0.000270228,0.0000715087,0.0002926286,0.9822467,0.0006038408,0.000629559,0.01317457],"study_design_scores_gemma":[0.0004070338,0.006133383,0.04131804,0.00006829297,0.000308642,0.003653041,0.000501405,0.00380649,0.9049093,0.0009004929,0.03796601,0.0000278507],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9939253,0.002932581,0.001003512,0.0002334242,0.00007146,0.0000185776,0.0001100198,0.00003014073,0.001675027],"genre_scores_gemma":[0.9966291,0.0009839864,0.0004397014,0.0001106789,0.00001313306,0.00001274014,0.000145781,0.00000439059,0.001660508],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002064836,"threshold_uncertainty_score":0.006907523,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W7117320530","doi":"10.1016/j.iotech.2025.101565","title":"350P Demystifying the biology behind a high neutrophil-to-lymphocyte ratio in gastroesophageal adenocarcinoma patients","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Montreal General Hospital; McGill University Health Centre","funders":"","keywords":"Adenocarcinoma; Disease; Cancer; MEDLINE; Esophageal adenocarcinoma","authors":[{"name":"I. Dhoparee Doomah","is_ca":true},{"name":"A. Brassard","is_ca":true},{"name":"Q. Qiu","is_ca":true},{"name":"R. Rohanizadeh","is_ca":true},{"name":"S. Leo","is_ca":true},{"name":"F. Bourdeau","is_ca":true},{"name":"B. Giannias","is_ca":true},{"name":"L. Ferri","is_ca":true},{"name":"J. Cools-Lartigue","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.00567843413252664,"gpt":0.2934156528470926,"spread":0.287737218714566,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004610188,0.0003258015,0.0003409576,0.0006608189,0.0002783797,0.001065683,0.0002587008,0.0005279006,0.001940329],"category_scores_gemma":[0.00140084,0.000127608,0.0001705689,0.0005768635,0.0003296554,0.0006313385,0.0003620549,0.0007900775,0.0004864527],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002945362,"about_ca_system_score_gemma":0.0002719165,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005400329,"about_ca_topic_score_gemma":0.0006588601,"domain_scores_codex":[0.9997624,0.00006669907,0.00002627879,0.00003546803,0.00006275151,0.00004644008],"domain_scores_gemma":[0.9995434,0.0001441779,0.0001205887,0.00002825634,0.00009591241,0.00006768906],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00134885,0.0001336684,0.8604348,0.0002185919,0.00009030513,0.00361665,0.0002865647,0.0002741618,0.02397774,0.001181934,0.00388535,0.1045513],"study_design_scores_gemma":[0.00009096356,0.001110172,0.9320228,0.0001999505,0.0003090268,0.0154134,0.001243651,0.003077089,0.02162648,0.003531562,0.02133879,0.00003617815],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9685324,0.01631986,0.002127593,0.003138025,0.0003005773,0.00005402319,0.0004234346,0.0001240195,0.008980069],"genre_scores_gemma":[0.9951615,0.00163218,0.001056379,0.0005554048,0.0002349327,0.0000240711,0.0001932665,0.000009553934,0.001132835],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001940329,"threshold_uncertainty_score":0.006491065,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W7117306831","doi":"10.1016/j.iotech.2025.101226","title":"142P Infusion time of adjuvant PD-1 therapy in high-risk resectable melanoma: Accounting for distance from clinic, scheduling changes over time, and appropriately adjusting p-values in SWOG S1404","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University Health Centre","funders":"Merck; Bristol-Myers Squibb","keywords":"Scheduling (production processes); Adjuvant; Adjuvant therapy; Continuous infusion","authors":[{"name":"S.P. Patel","is_ca":false},{"name":"K. Kendra","is_ca":false},{"name":"K.F. Grossmann","is_ca":false},{"name":"E. Buchbinder","is_ca":false},{"name":"N.I. Khushalani","is_ca":false},{"name":"Z. Eroglu","is_ca":false},{"name":"S. Chandra","is_ca":false},{"name":"G. Doolittle","is_ca":false},{"name":"J.M. Kirkwood","is_ca":false},{"name":"A. Ikeguchi","is_ca":false},{"name":"C. Mihalcioiu","is_ca":true},{"name":"C.L. Cowey","is_ca":false},{"name":"S.A. Reddy","is_ca":false},{"name":"D. Johnson","is_ca":false},{"name":"M. Taylor","is_ca":false},{"name":"V. Sondak","is_ca":false},{"name":"A. Ribas","is_ca":false},{"name":"M. Othus","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01078010469760657,"gpt":0.2866931739268872,"spread":0.2759130692292807,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007267534,0.0003961199,0.0008041058,0.0004625033,0.0003005754,0.001179159,0.001132027,0.000565339,0.003591602],"category_scores_gemma":[0.02694602,0.000282358,0.001508327,0.001076456,0.000280274,0.001006415,0.0004987272,0.001650804,0.000422306],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008658115,"about_ca_system_score_gemma":0.00141949,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.007056094,"about_ca_topic_score_gemma":0.006928582,"domain_scores_codex":[0.995702,0.001967219,0.0003549283,0.001152655,0.000466914,0.000356256],"domain_scores_gemma":[0.9825472,0.01321214,0.001827461,0.001297086,0.0005174586,0.0005986464],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01440448,0.000376523,0.788766,0.0002715688,0.003944681,0.0005333793,0.0002689689,0.03105602,0.002712516,0.001124202,0.006018869,0.1505228],"study_design_scores_gemma":[0.0004916032,0.002470958,0.7316557,0.0001330328,0.003064526,0.0009226488,0.0004950759,0.2379757,0.005189328,0.003612409,0.01392152,0.00006741226],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9710298,0.002172989,0.01981819,0.001067226,0.0005681767,0.0000486868,0.00188935,0.0002444919,0.003161046],"genre_scores_gemma":[0.9940978,0.000104706,0.003666381,0.0001152712,0.00005852722,0.00003431318,0.0005429199,0.0001072488,0.001272766],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007267534,"threshold_uncertainty_score":0.03843486,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W7117312005","doi":"10.1016/j.iotech.2025.101572","title":"395P Synthetic IL-12 immunotherapy reverses immune suppression and halts metastasis in pancreatic cancer","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Immunotherapy; Pancreatic cancer; Immune system; Pancreatic ductal adenocarcinoma; Metastasis; Cytokine; Infiltration (HVAC); Tumor microenvironment","authors":[{"name":"C. Ragulan","is_ca":true},{"name":"M. Herpels","is_ca":true},{"name":"G. Box","is_ca":false},{"name":"Y. Ikami","is_ca":true},{"name":"R. Luo","is_ca":true},{"name":"L. Howell","is_ca":true},{"name":"E. Westlund","is_ca":true},{"name":"A. De Haven Brandon","is_ca":false},{"name":"N. Guppy","is_ca":false},{"name":"E. Wennerberg","is_ca":false},{"name":"J. Ishihara","is_ca":false},{"name":"A. Sadanandam","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01692823134436916,"gpt":0.3463640821661589,"spread":0.3294358508217897,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001132995,0.0002394379,0.0002164858,0.0002213744,0.000107909,0.0002169386,0.0001886747,0.0002644962,0.002049252],"category_scores_gemma":[0.0000891189,0.00009300623,0.0001444799,0.0001406761,0.0002679599,0.0001657048,0.0001542326,0.0009062169,0.0004513502],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002222105,"about_ca_system_score_gemma":0.0003012602,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00040586,"about_ca_topic_score_gemma":0.0006374914,"domain_scores_codex":[0.9999191,0.00001255269,0.000005006116,0.00001150798,0.00002934079,0.00002255109],"domain_scores_gemma":[0.9999604,0.000007693955,0.000007330584,0.000005023694,0.000003969898,0.00001570654],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0007196939,0.0002923496,0.0001061111,0.0001137613,0.000009697899,0.0001198754,0.00002841035,0.0008871291,0.9834012,0.0004772374,0.0005543931,0.01329009],"study_design_scores_gemma":[0.0002946884,0.003280137,0.00117245,0.0000142767,0.00002577703,0.0004487385,0.00003129464,0.003442748,0.9785265,0.0002246976,0.01252983,0.000008929926],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9849609,0.004263313,0.005247604,0.000565634,0.0002116403,0.00006099149,0.000361854,0.0003585052,0.003969651],"genre_scores_gemma":[0.990684,0.001637082,0.002528717,0.0001073861,0.00002544403,0.00005125376,0.0003645768,0.00003382111,0.004567671],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002049252,"threshold_uncertainty_score":0.006855369,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W7117291323","doi":"10.1016/j.iotech.2025.101225","title":"141P Clinical study of camrelizumab combined with SOX in adjuvant therapy for gastric or gastroesophageal junction adenocarcinoma: Interim report","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Jonsson Comprehensive Cancer Center; University of Colorado Denver; University of Pittsburgh; Medical Center, University of Pittsburgh; Vanderbilt University Medical Center; McGill University Health Centre; McGill University; Northwestern University; University of Texas MD Anderson Cancer Center; School of Medicine, Stanford University; Vanderbilt University; Moffitt Cancer Center; Ohio State University","keywords":"Clinical study; Gastroesophageal Junction; Adjuvant therapy; Clinical trial; Adjuvant; Interim; Interim analysis","authors":[{"name":"Q. Yi","is_ca":false},{"name":"H. Liu","is_ca":false},{"name":"J. Liu","is_ca":false},{"name":"Z. Xiao","is_ca":false},{"name":"Q. Li","is_ca":false},{"name":"C. Wei","is_ca":false},{"name":"M. Jiao","is_ca":false},{"name":"C. Su","is_ca":false},{"name":"C. Wang","is_ca":false},{"name":"K. Li","is_ca":false},{"name":"L. Ma","is_ca":false},{"name":"M. Li","is_ca":false},{"name":"Y. Kong","is_ca":false},{"name":"Y. Wen","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03616686054081508,"gpt":0.384055794376691,"spread":0.3478889338358759,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001781934,0.0005135106,0.001036566,0.0002074457,0.000283143,0.001031106,0.0003792896,0.001037451,0.007354795],"category_scores_gemma":[0.001564445,0.0001976558,0.001482403,0.0003821696,0.000333961,0.0005933105,0.0003419626,0.001974679,0.001752478],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006027176,"about_ca_system_score_gemma":0.001273539,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004529955,"about_ca_topic_score_gemma":0.0008599107,"domain_scores_codex":[0.9994585,0.0002282483,0.00005251052,0.0000701391,0.00009531769,0.00009527407],"domain_scores_gemma":[0.9992862,0.0001412055,0.0001315334,0.00007091245,0.0001029651,0.0002672061],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5191137,0.01839335,0.02489849,0.004677134,0.005263098,0.001753693,0.0002684153,0.001556699,0.01969842,0.0009477656,0.03584139,0.3675878],"study_design_scores_gemma":[0.3296034,0.5090404,0.06242285,0.000868861,0.004361531,0.001959591,0.000136478,0.00136617,0.007970582,0.0009295428,0.08127813,0.00006252715],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8913063,0.03660703,0.002394308,0.007749299,0.002078155,0.009855422,0.01362517,0.0002675453,0.03611667],"genre_scores_gemma":[0.9459232,0.01352229,0.003048116,0.006043219,0.001513534,0.005007355,0.01312401,0.00005312608,0.01176522],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007354795,"threshold_uncertainty_score":0.02460426,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4405374307","doi":"10.1016/j.iotech.2024.100796","title":"168TiP A phase I dose escalation/expansion study of GSK5764227 (GSK’227), a B7-homolog 3 (B7-H3) protein targeted antibody-drug conjugate (ADC), in patients with advanced solid tumours","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Medical Imaging Techniques and Applications","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Hospital","funders":"Institut National Du Cancer; Eisai; Fondation ARC pour la Recherche sur le Cancer; Seagen; Astellas Pharma; NuCana; Sanofi; Exelixis; BeiGene; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Conjugate; Antibody-drug conjugate; Antibody; Medicine; Drug; Cancer research; Monoclonal antibody; Pharmacology; Immunology; Mathematics","authors":[{"name":"G. Curigliano","is_ca":false},{"name":"P. Cassier","is_ca":false},{"name":"Gennaro Daniele","is_ca":false},{"name":"John Hilton","is_ca":true},{"name":"A. Italiano","is_ca":false},{"name":"Shigeki KOGANEMARU","is_ca":false},{"name":"Rubén Dario Kowalyszyn","is_ca":false},{"name":"P. LoRusso","is_ca":false},{"name":"V. Moreno Garcia","is_ca":false},{"name":"M.E. Olmedo García","is_ca":false},{"name":"Herman Andrés Perroud","is_ca":false},{"name":"Wasif M. Saif","is_ca":false},{"name":"Stefan N. Symeonides","is_ca":false},{"name":"A. Aziez","is_ca":false},{"name":"Rana Anjum","is_ca":false},{"name":"John LaMacchia","is_ca":false},{"name":"Harjeet Sembhi","is_ca":false},{"name":"Nirav Ratia","is_ca":false},{"name":"N. Yamamoto","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.007515845738382482,"gpt":0.342843778635392,"spread":0.3353279328970095,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004405006,0.0008325378,0.0009925081,0.0003401575,0.0002577347,0.0007099393,0.0004917659,0.0008629145,0.005243259],"category_scores_gemma":[0.0003724207,0.0003886131,0.0008744631,0.0002838352,0.0005378152,0.0005007915,0.0002345244,0.003343496,0.001605028],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005883814,"about_ca_system_score_gemma":0.0009324507,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001239714,"about_ca_topic_score_gemma":0.002069412,"domain_scores_codex":[0.9998345,0.00004554596,0.000007944807,0.00002881435,0.00002261153,0.00006047172],"domain_scores_gemma":[0.9997905,0.00002887814,0.00002380764,0.00002445665,0.00001680389,0.0001154902],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.348612,0.09318656,0.005824485,0.001196142,0.001247647,0.000849777,0.000487246,0.00633571,0.2347343,0.001134776,0.02099846,0.2853929],"study_design_scores_gemma":[0.3590004,0.5868213,0.01123613,0.00005230906,0.0005153039,0.0007283782,0.0001000815,0.002956323,0.02656339,0.0004035508,0.01157361,0.00004919693],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9889317,0.00175812,0.0008042096,0.0007985807,0.0002180602,0.001453106,0.001363495,0.0002236397,0.004449042],"genre_scores_gemma":[0.9840443,0.00147366,0.001916665,0.0008602854,0.00009614522,0.001446259,0.003098497,0.00004797605,0.007016197],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005243259,"threshold_uncertainty_score":0.01754051,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W7117296119","doi":"10.1016/j.iotech.2025.101450","title":"251P Final results of the FAK-PD1 phase I/IIA study of FAK (defactinib) and PD-1 (pembrolizumab) inhibition in advanced solid tumours","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"NIH Clinical Center; University of California, San Diego; Genentech; Sierra Oncology; Ipsen; Servier; Weill Cornell Medical College; National Institute for Health and Care Research; Seagen; Sidney Kimmel Comprehensive Cancer Center; Pfizer; Moderna; NuCana; Incyte; Boston Pharmaceuticals; Cancer Research UK; Verastem Oncology; Amgen; Barbara Ann Karmanos Cancer Institute; BeiGene; Les Laboratories Pierre Fabre; Moffitt Cancer Center; Sanofi; Exelixis; Astellas Pharma; Eisai; Thomas Jefferson University; Johns Hopkins University; Celgene; Institut National Du Cancer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Phase (matter); Cancer; Solid tumor; Cytotoxicity","authors":[{"name":"S.N. Symeonides","is_ca":false},{"name":"T.R.J. Evans","is_ca":false},{"name":"D. A. Fennell","is_ca":false},{"name":"V. Coyle","is_ca":false},{"name":"I. Karydis","is_ca":false},{"name":"A. Oswald","is_ca":false},{"name":"L. Sweeting","is_ca":false},{"name":"C. Macbride","is_ca":false},{"name":"J. McQueen","is_ca":false},{"name":"A. Coleman","is_ca":false},{"name":"T. Wynn","is_ca":false},{"name":"K. Boukas","is_ca":false},{"name":"A. Serrels","is_ca":false},{"name":"C.H.H. Ottensmeier","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02047705227220095,"gpt":0.385868474467102,"spread":0.3653914221949011,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002125741,0.001146572,0.0009651005,0.0003821708,0.0005839816,0.001231365,0.0008411735,0.001750359,0.006891348],"category_scores_gemma":[0.0007996411,0.0003934152,0.001177992,0.0001786356,0.0004421129,0.0002940956,0.0004516571,0.001926566,0.002302183],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001022835,"about_ca_system_score_gemma":0.001452606,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002427127,"about_ca_topic_score_gemma":0.004333248,"domain_scores_codex":[0.9994136,0.0001998809,0.00003129207,0.00006433993,0.0001511673,0.0001396651],"domain_scores_gemma":[0.9994496,0.00008604148,0.00003209009,0.00003487501,0.0001159468,0.0002815163],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2144213,0.01565322,0.004417522,0.001315639,0.002505181,0.002546239,0.0001718184,0.003531454,0.1628907,0.001451542,0.3498106,0.2412848],"study_design_scores_gemma":[0.2044742,0.2320218,0.05871495,0.0002852514,0.003400809,0.003320236,0.0001344291,0.004081558,0.15517,0.001916999,0.3363363,0.0001433691],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.6863329,0.04010978,0.01143401,0.03447973,0.01274022,0.01301192,0.05784782,0.001240493,0.1428031],"genre_scores_gemma":[0.7297167,0.01650814,0.01383585,0.02005379,0.003583398,0.004700373,0.06661545,0.0005476069,0.1444388],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006891348,"threshold_uncertainty_score":0.02305382,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4407087806","doi":"10.1016/j.iotech.2025.101042","title":"Challenges and opportunities of predicting overall survival benefit from improvements to recurrence-free survival in stage II/III melanoma: a correlation meta-analysis","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Celgene; Bristol-Myers Squibb Canada; Bristol-Myers Squibb","keywords":"Stage (stratigraphy); Meta-analysis; Overall survival; Correlation; Melanoma; Oncology; Internal medicine; Survival analysis; Medicine; Biology; Mathematics; Cancer research","authors":[{"name":"LP Leung","is_ca":false},{"name":"John M. Kirkwood","is_ca":false},{"name":"S. Srinivasan","is_ca":false},{"name":"M Dyer","is_ca":false},{"name":"A Qian","is_ca":false},{"name":"MM. Pourrahmat","is_ca":false},{"name":"Ellen Kasireddy","is_ca":false},{"name":"J. Robert May","is_ca":false},{"name":"Andriy Moshyk","is_ca":false},{"name":"Murat Kurt","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.07049526614308026,"gpt":0.3109782898953646,"spread":0.2404830237522843,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.1309706,0.003126578,0.01128408,0.005861838,0.0004602892,0.005729032,0.002348405,0.001603334,0.002544245],"category_scores_gemma":[0.2282776,0.001467749,0.0350067,0.004992807,0.001161307,0.002742122,0.002367788,0.003500603,0.0003784257],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001832837,"about_ca_system_score_gemma":0.003832525,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003467443,"about_ca_topic_score_gemma":0.004842442,"domain_scores_codex":[0.9104933,0.07402268,0.007667121,0.004191295,0.003058409,0.0005671287],"domain_scores_gemma":[0.7430065,0.2272871,0.0144841,0.009270404,0.005231439,0.0007204924],"domain_codex":null,"domain_gemma":"methods","domain_candidate":"methods","domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.001596596,0.00003017092,0.01883712,0.06846222,0.857779,0.0001418674,0.0001124045,0.004711932,0.0002400228,0.001977439,0.001589161,0.04452205],"study_design_scores_gemma":[0.0006596084,0.0004603955,0.009553472,0.01873005,0.9484038,0.0001882176,0.00008300415,0.004980149,0.0003236312,0.0102719,0.00628082,0.00006490685],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.008812406,0.9628192,0.0200939,0.005031223,0.0006381521,0.0004493645,0.0008041605,0.0001548457,0.001196805],"genre_scores_gemma":[0.622089,0.3258057,0.03716839,0.008419817,0.001981064,0.002239238,0.001316271,0.0002638803,0.0007165968],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.8690294,"threshold_uncertainty_score":0.692647,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W7117304384","doi":"10.1016/j.iotech.2025.101199","title":"114P Exploring the role of FES kinase in natural killer cells to enhance immunotherapy","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University","funders":"","keywords":"Immunotherapy; Kinase; Immune system; Natural killer cell; Cancer immunotherapy; Tyrosine kinase","authors":[{"name":"A.A. Varty-Higgs","is_ca":true},{"name":"J. Simonetti","is_ca":true},{"name":"B.J. Laight","is_ca":true},{"name":"P.A. Greer","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.006114528020794343,"gpt":0.2639369299625833,"spread":0.257822401941789,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002043981,0.0003442404,0.0001553472,0.0001581163,0.00009325551,0.0003447797,0.0002374681,0.0004008279,0.004495203],"category_scores_gemma":[0.0001225689,0.00006818409,0.0001972651,0.00008660001,0.0002292434,0.0003179814,0.0001854221,0.0005086139,0.0007847784],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003747538,"about_ca_system_score_gemma":0.0002566832,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001906544,"about_ca_topic_score_gemma":0.0002794757,"domain_scores_codex":[0.9999449,0.00000946322,0.000003412244,0.000007696149,0.00001693507,0.00001748818],"domain_scores_gemma":[0.9999644,0.000008742607,0.000007723907,0.000002563137,0.000007665116,0.00000891113],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.000801118,0.0002809094,0.0004951038,0.0004638304,0.00001868729,0.0002307278,0.00003017153,0.001101822,0.9390634,0.002774462,0.00142078,0.05331909],"study_design_scores_gemma":[0.0006523498,0.005730366,0.003432941,0.0001396685,0.00006139342,0.001456387,0.00006597472,0.004964101,0.9061073,0.002086322,0.07528597,0.00001735932],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9176726,0.04052369,0.01445887,0.003425906,0.0005130598,0.0004071718,0.0005323177,0.0002250944,0.02224124],"genre_scores_gemma":[0.964068,0.01379729,0.006993372,0.00036411,0.00008374433,0.000128194,0.0004643232,0.00001839124,0.01408254],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004495203,"threshold_uncertainty_score":0.01503795,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4310923624","doi":"10.1016/j.iotech.2022.100230","title":"241P Treatment and outcomes of patients with gastrointestinal toxicity following immunotherapy: A large multi-center retrospective study in the United Kingdom by the National Oncology Trainees Collaborative for Healthcare Research (NOTCH)","year":2022,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Center (category theory); Retrospective cohort study; Health care; Immunotherapy; Toxicity; Internal medicine; Family medicine; Oncology; Cancer; Political science","authors":[{"name":"M. Swaminathan","is_ca":false},{"name":"A. Angelakas","is_ca":false},{"name":"Monica L. Baxter","is_ca":false},{"name":"J. Cotton","is_ca":false},{"name":"C.B. Dobeson","is_ca":false},{"name":"L. Feeney","is_ca":false},{"name":"A.C. Gault","is_ca":false},{"name":"D.J. Hughes","is_ca":false},{"name":"Cheryl Page Jones","is_ca":false},{"name":"R. Lee","is_ca":false},{"name":"Shahrauz Mughal","is_ca":false},{"name":"S.P. Parikh","is_ca":false},{"name":"M. Pritchard","is_ca":false},{"name":"L.J. Rodgers","is_ca":false},{"name":"M.P. Rowe","is_ca":false},{"name":"A.T. Salawu","is_ca":true},{"name":"R. Shotton","is_ca":false},{"name":"Nadina Tinsley","is_ca":false},{"name":"Ann Tivey","is_ca":false},{"name":"A.C. Olsson-Brown","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05952476980682447,"gpt":0.4100764466070851,"spread":0.3505516768002606,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005655543,0.0002658638,0.0006591803,0.0004572564,0.0004936918,0.0009746802,0.0003655994,0.0006759884,0.001462032],"category_scores_gemma":[0.002111458,0.0003512338,0.0009067929,0.001497209,0.0003362622,0.0004997515,0.0005890875,0.0007977347,0.0002683035],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008713225,"about_ca_system_score_gemma":0.0004844836,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00683593,"about_ca_topic_score_gemma":0.006715561,"domain_scores_codex":[0.9990331,0.0002313995,0.0001511275,0.0002621754,0.0001565975,0.0001656285],"domain_scores_gemma":[0.9977719,0.0003423298,0.001212796,0.0001692964,0.000223767,0.0002799614],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0004841305,0.00001844607,0.9976676,0.00003320983,0.0001789018,0.000188862,0.00004508485,0.00003478804,0.0001814061,0.00001545977,0.0002129088,0.0009391786],"study_design_scores_gemma":[0.0000282702,0.0001515047,0.9985909,0.00001767047,0.000100575,0.0005458936,0.000100823,0.00005797395,0.00004645774,0.00001171715,0.0003416362,0.000006502574],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9963581,0.002045278,0.00007100901,0.00009979964,0.00001086782,0.00001210875,0.00096829,0.000002912947,0.0004317593],"genre_scores_gemma":[0.9984605,0.000345339,0.00003304841,0.00009503799,0.00001402768,0.00001178569,0.0009229934,0.000003269797,0.0001140451],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00683593,"threshold_uncertainty_score":0.0135923,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W7117317538","doi":"10.1016/j.iotech.2025.101406","title":"409P Spatial profiling of tumour-infiltrating B cells reveals immune shifts in rapidly progressing cholangiocarcinoma","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Terry Fox Foundation","keywords":"Immune system; Antibody; Profiling (computer programming); Gene expression profiling; B cell; Phenotype","authors":[{"name":"S. Yangngam","is_ca":false},{"name":"C.J. O'Rourke","is_ca":false},{"name":"O. Nousias","is_ca":false},{"name":"J. Andersen","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0122694007136765,"gpt":0.3009349530357847,"spread":0.2886655523221082,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000113642,0.0001001953,0.00009921326,0.0004645036,0.0001645326,0.0003050478,0.0001054492,0.0002093337,0.002119565],"category_scores_gemma":[0.0001462054,0.0001149963,0.0001047629,0.0003124546,0.0001944488,0.0001951398,0.0001839215,0.0002683063,0.000540288],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001056897,"about_ca_system_score_gemma":0.00007090544,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005403087,"about_ca_topic_score_gemma":0.0004937968,"domain_scores_codex":[0.9999355,0.00000960823,0.000003704649,0.00001395607,0.00001140041,0.00002573246],"domain_scores_gemma":[0.999938,0.00001466321,0.00001213726,0.000008331547,0.00001152954,0.00001524077],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.0005084468,0.00001696183,0.007310955,0.00002380622,0.000006436546,0.0001966722,0.00006920685,0.00007635068,0.9884114,0.0001163086,0.00004018773,0.003223223],"study_design_scores_gemma":[0.00003030417,0.0006334661,0.3742373,0.00001435479,0.00006297887,0.003649922,0.001087026,0.002110335,0.6124987,0.0005757103,0.005085364,0.00001442704],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9973162,0.0003609937,0.0007585762,0.00001945557,0.000003424436,0.000003413409,0.0001057151,0.00001487292,0.001417264],"genre_scores_gemma":[0.9979474,0.0002024015,0.0005661552,0.00001989475,0.000004048279,0.000009570234,0.0001250412,0.00000790954,0.001117597],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002119565,"threshold_uncertainty_score":0.007090688,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4389480834","doi":"10.1016/j.iotech.2023.100668","title":"157TiP Krascendo-170 Lung: A phase Ib/II study of divarasib + pembrolizumab ± platinum-based chemotherapy and pemetrexed in untreated KRAS G12C+ advanced non-small cell lung cancer (NSCLC)","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Genentech; Ipsen; Sanofi; Bayer HealthCare; F. Hoffmann-La Roche; Incyte; Natera; Amgen; ViiV Healthcare; Eisai; AstraZeneca; Bristol-Myers Squibb","keywords":"Pemetrexed; Pembrolizumab; Medicine; Lung cancer; Chemotherapy; Oncology; KRAS; Internal medicine; Lung; Cancer; Cisplatin; Colorectal cancer; Immunotherapy","authors":[{"name":"Ferdinandos Skoulidis","is_ca":false},{"name":"Kristof Cuppens","is_ca":false},{"name":"Adrian G. Sacher","is_ca":true},{"name":"Vamsidhar Velcheti","is_ca":false},{"name":"D.H. Lee","is_ca":false},{"name":"M.T. Lin","is_ca":false},{"name":"T.M. Fernando","is_ca":false},{"name":"S. Li","is_ca":false},{"name":"David Bradley","is_ca":false},{"name":"Marija Crnković","is_ca":false},{"name":"Mariann Mathisen","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01084802645926599,"gpt":0.3612404445660097,"spread":0.3503924181067438,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001041958,0.001400051,0.00178757,0.0003771193,0.0003170282,0.001175698,0.0009753337,0.001246397,0.004860419],"category_scores_gemma":[0.0004590752,0.0006787213,0.001497765,0.0003579932,0.0008002971,0.0007273642,0.0003242559,0.003469133,0.001540091],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009821375,"about_ca_system_score_gemma":0.001976928,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001276402,"about_ca_topic_score_gemma":0.004040854,"domain_scores_codex":[0.9997366,0.00008736388,0.0000153528,0.00005407779,0.00003672056,0.00006988169],"domain_scores_gemma":[0.9995834,0.00004023442,0.00005204934,0.00003026281,0.00003173927,0.0002623186],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6662543,0.1402676,0.005258711,0.001987862,0.002012314,0.0003352848,0.0002835061,0.002296743,0.07074726,0.0005945044,0.00661542,0.1033465],"study_design_scores_gemma":[0.4926857,0.4890209,0.00694213,0.00006661181,0.0006270421,0.0003375127,0.00009207529,0.0008942548,0.004434805,0.0002063494,0.004655788,0.00003688377],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9873446,0.003123881,0.0004270047,0.0004845362,0.0002315751,0.003486193,0.001576387,0.000146311,0.003179542],"genre_scores_gemma":[0.9771873,0.004539249,0.001856678,0.001494213,0.0002166537,0.003331796,0.005585755,0.00005141151,0.005736835],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004860419,"threshold_uncertainty_score":0.01625979,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4389480990","doi":"10.1016/j.iotech.2023.100488","title":"19P The prognostic value of soluble CD73 in advanced triple-negative breast cancer: An exploratory analysis of the SYNERGY trial","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal","funders":"Stichting Tegen Kanker","keywords":"Breast cancer; Oncology; Triple-negative breast cancer; Internal medicine; Value (mathematics); Exploratory analysis; Medicine; Cancer; Statistics; Mathematics; Computer science; Data science","authors":[{"name":"Zoe Davey","is_ca":false},{"name":"Paulus Kristanto","is_ca":false},{"name":"Xavier Catteau","is_ca":false},{"name":"Delphine Vincent","is_ca":false},{"name":"Véronique Debien","is_ca":false},{"name":"Elisa Agostinetto","is_ca":false},{"name":"John Stagg","is_ca":true},{"name":"Roberto Salgado","is_ca":false},{"name":"Denis Larsimont","is_ca":false},{"name":"Christos Sotiriou","is_ca":false},{"name":"Françoise Rothé","is_ca":false},{"name":"Laurence Buisseret","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01088496838347184,"gpt":0.2894655851583049,"spread":0.2785806167748331,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00200246,0.0005702366,0.001085737,0.0001958629,0.0001998825,0.0006572495,0.0002714619,0.0004965272,0.002734561],"category_scores_gemma":[0.001807471,0.0001784104,0.001135997,0.0003293052,0.0003173587,0.000473799,0.0004640361,0.001086416,0.0004254019],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000433665,"about_ca_system_score_gemma":0.0005635244,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003149507,"about_ca_topic_score_gemma":0.0007473917,"domain_scores_codex":[0.9992762,0.0004385985,0.00004202211,0.0000930728,0.00007507815,0.00007505031],"domain_scores_gemma":[0.9988229,0.0003937472,0.0003121695,0.000104885,0.00008081063,0.0002854377],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.8956929,0.001779609,0.05286537,0.0004681762,0.003971759,0.0001752347,0.00008675078,0.0009045391,0.006172766,0.0001833023,0.002533549,0.03516612],"study_design_scores_gemma":[0.4065026,0.2799299,0.2795298,0.0002003637,0.01272247,0.0009378336,0.0002063221,0.005143577,0.004205378,0.001177809,0.009368445,0.00007554218],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9943871,0.002119916,0.0002164493,0.0003756379,0.00006330891,0.0002403808,0.001366746,0.0000209503,0.001209474],"genre_scores_gemma":[0.9958044,0.0006777192,0.0003910164,0.000245415,0.0001812783,0.00028332,0.001722589,0.000007806669,0.0006864905],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002734561,"threshold_uncertainty_score":0.01059014,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4389487916","doi":"10.1016/j.iotech.2023.100553","title":"81P Real-world experience with docetaxel regimens in metastatic non-squamous (mNSq) non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy (PCT) and an immune checkpoint inhibitor (ICI) in the United States (US)","year":2023,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"MD Precision (Canada)","funders":"Sanofi","keywords":"Docetaxel; Medicine; Internal medicine; Discontinuation; Oncology; Lung cancer; Chemotherapy; Confidence interval; Progression-free survival; Retrospective cohort study; Response Evaluation Criteria in Solid Tumors; Performance status; Progressive disease","authors":[{"name":"Marisa A. Bittoni","is_ca":false},{"name":"Sam Keeping","is_ca":true},{"name":"David P. Carbone","is_ca":false},{"name":"J.E. Park","is_ca":true},{"name":"A.T.H. Nguyen","is_ca":false},{"name":"K. Toor","is_ca":true},{"name":"Natalia Petruski‐Ivleva","is_ca":false},{"name":"A.K. Vadanahalli Shankar","is_ca":false},{"name":"Gerasimos Konidaris","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01099841336355249,"gpt":0.3132831200810172,"spread":0.3022847067174647,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007179138,0.0001074917,0.0002433816,0.00025318,0.0004085746,0.0008619526,0.0001982422,0.0001941754,0.0008426447],"category_scores_gemma":[0.002221684,0.000177883,0.000493801,0.0005278448,0.0002590708,0.0004423203,0.0004558435,0.0003740337,0.0002226568],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008164221,"about_ca_system_score_gemma":0.0006204451,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004363117,"about_ca_topic_score_gemma":0.009697439,"domain_scores_codex":[0.9994993,0.0001402253,0.00006893641,0.0001138626,0.00009778759,0.00007980451],"domain_scores_gemma":[0.9986051,0.0002362986,0.0007758242,0.000111429,0.00009434353,0.0001769664],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.000792855,0.0002199561,0.9891082,0.00003315281,0.00008937943,0.0004404542,0.0002791655,0.0001839398,0.0003740944,0.00005499233,0.0003821503,0.008041583],"study_design_scores_gemma":[0.0001404048,0.00236494,0.9875065,0.00003534574,0.0001443227,0.003096752,0.0007782995,0.0008505886,0.0005883152,0.00008229157,0.004391657,0.00002068124],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.99873,0.0002356117,0.00006128792,0.00004615251,0.000004179223,0.0000197016,0.0004718302,0.000002001161,0.0004292017],"genre_scores_gemma":[0.9985663,0.0002933348,0.00009220917,0.00006516075,0.00001210361,0.00001697929,0.0007650214,0.000002282118,0.0001866254],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004363117,"threshold_uncertainty_score":0.008675456,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4310923924","doi":"10.1016/j.iotech.2022.100213","title":"109P Impact of anti-drug antibody (ADA) on naxitamab efficacy and safety","year":2022,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Drug; Medicine; Pharmacology","authors":[{"name":"Brian H. Kushner","is_ca":false},{"name":"G.C. Chan","is_ca":false},{"name":"D.A. Morgenstern","is_ca":true},{"name":"L. Amoroso","is_ca":false},{"name":"K. Nysom","is_ca":false},{"name":"J. Faber","is_ca":false},{"name":"A. Wingerter","is_ca":false},{"name":"M. Bear","is_ca":false},{"name":"A. Rubio San Simon","is_ca":false},{"name":"K. Tornøe","is_ca":false},{"name":"P.S. Sørensen","is_ca":false},{"name":"J. Mora","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01469282178462866,"gpt":0.3674672308365919,"spread":0.3527744090519632,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001285166,0.0001846717,0.0005047594,0.0001654711,0.000196727,0.0008339504,0.0003202122,0.0005651898,0.0155631],"category_scores_gemma":[0.00287929,0.0001079333,0.0005207421,0.000207762,0.0003583396,0.0003373465,0.0002694362,0.001368473,0.001937409],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007979171,"about_ca_system_score_gemma":0.0008248267,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001421059,"about_ca_topic_score_gemma":0.002376999,"domain_scores_codex":[0.9989774,0.0003833224,0.00006617865,0.00007522045,0.000386666,0.0001111711],"domain_scores_gemma":[0.9989763,0.0004970133,0.0001550216,0.0000619048,0.0001924323,0.0001172586],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.03290374,0.002931301,0.01785503,0.001718293,0.000762148,0.001052441,0.000121373,0.002345261,0.1252463,0.003762084,0.05597731,0.7553248],"study_design_scores_gemma":[0.01773536,0.1488115,0.1760378,0.00123504,0.002114903,0.006158533,0.0002954706,0.01268227,0.2419503,0.006240875,0.3866134,0.0001246314],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8498021,0.02903675,0.004471687,0.01176073,0.001439734,0.001272631,0.008241002,0.0003656762,0.09360972],"genre_scores_gemma":[0.9770871,0.004589999,0.002326135,0.002674902,0.0002989852,0.0003909928,0.002372411,0.0000921362,0.01016737],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0155631,"threshold_uncertainty_score":0.05206376,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4405374842","doi":"10.1016/j.iotech.2024.100889","title":"5MO Novel radiologic phenotypes of chaotic tumor angiogenesis associated with poor ICI outcomes in NSCLC","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Artificial Intelligence in Medicine (Canada)","funders":"Syöpäsäätiö; Helsingin Yliopisto; Jane ja Aatos Erkon Säätiö; Ida Montinin Säätiö","keywords":"Angiogenesis; Phenotype; Chaotic; Medicine; Oncology; Internal medicine; Cancer research; Computer science; Biology; Genetics; Gene; Artificial intelligence","authors":[{"name":"Vamsidhar Velcheti","is_ca":false},{"name":"Rhea Chitalia","is_ca":false},{"name":"Carla Leibowitz","is_ca":false},{"name":"Kai Zhang","is_ca":true},{"name":"Anant Madabhushi","is_ca":false},{"name":"Nathaniel Braman","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01844260851793054,"gpt":0.274020598656686,"spread":0.2555779901387555,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002898893,0.0002797305,0.0001475325,0.0008139469,0.0002187081,0.0005892161,0.0001906282,0.0003876743,0.002233714],"category_scores_gemma":[0.0006743823,0.000117167,0.0002374075,0.0003826866,0.0002710691,0.0002822643,0.0003449924,0.0003593819,0.0002434354],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003103864,"about_ca_system_score_gemma":0.0001862359,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008293734,"about_ca_topic_score_gemma":0.0008150176,"domain_scores_codex":[0.9999037,0.00001877097,0.000008165267,0.00002289593,0.00001791463,0.00002853412],"domain_scores_gemma":[0.9995661,0.00005683938,0.0002219695,0.00002240032,0.00006098587,0.00007161064],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001418352,0.0001170224,0.8785847,0.0001160854,0.0001195432,0.002651651,0.0001602719,0.0006212666,0.08779264,0.00114883,0.00109915,0.02617049],"study_design_scores_gemma":[0.00003296134,0.0003322176,0.9771593,0.00002297016,0.00009787063,0.005516239,0.0001985067,0.002362169,0.01115274,0.0008963783,0.00221483,0.00001377853],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.995175,0.0006946002,0.0009840442,0.0001979183,0.00001541959,0.00001868778,0.0003266714,0.00003008799,0.002557636],"genre_scores_gemma":[0.9989063,0.0001167003,0.0003603944,0.00003194882,0.00001933845,0.0000109831,0.0002077413,0.000003881095,0.0003428744],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002233714,"threshold_uncertainty_score":0.007472515,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4405374998","doi":"10.1016/j.iotech.2024.100749","title":"120MO Inupadenant combined with chemotherapy in patients with non-squamous NSCLC progressing on or after immune checkpoint inhibitor therapy: Results from dose-finding part of the A2A-005 trial","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"William Osler Health System; Brampton Civic Hospital","funders":"","keywords":"Medicine; Oncology; Chemotherapy; Internal medicine; Immune checkpoint; Immune system; Immunotherapy; Immunology; Cancer","authors":[{"name":"Kristof Cuppens","is_ca":false},{"name":"G. Lo Russo","is_ca":false},{"name":"Óscar Juan","is_ca":false},{"name":"E. Felip","is_ca":false},{"name":"Ma Carmen Areses Manrique","is_ca":false},{"name":"Alberto Chiappori","is_ca":false},{"name":"E. Govaerts","is_ca":false},{"name":"P.K. Cheema","is_ca":true},{"name":"L. Greillier","is_ca":false},{"name":"L. Toschi","is_ca":false},{"name":"Eric Schaefer","is_ca":false},{"name":"M. Clouseau","is_ca":false},{"name":"C. Martinoli","is_ca":false},{"name":"Hussein Shehade","is_ca":false},{"name":"Natalie Byrne","is_ca":false},{"name":"M. Fox","is_ca":false},{"name":"M. Rossetti","is_ca":false},{"name":"Olivier De Henau","is_ca":false},{"name":"S. Ross","is_ca":false},{"name":"S. Peters","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01290091525342313,"gpt":0.2756339601567856,"spread":0.2627330449033625,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007583913,0.0006755997,0.001151088,0.0002104823,0.0001886227,0.0008164323,0.0004011828,0.000605406,0.002419481],"category_scores_gemma":[0.000392437,0.0002027601,0.001189288,0.0002542895,0.0003549605,0.0005108906,0.0002419134,0.001543927,0.0004133062],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006022121,"about_ca_system_score_gemma":0.000619167,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006488094,"about_ca_topic_score_gemma":0.001741382,"domain_scores_codex":[0.9997457,0.0001282542,0.00001457192,0.00004194145,0.00002182684,0.00004779374],"domain_scores_gemma":[0.9997855,0.00003390166,0.00004879298,0.00001874641,0.00001196891,0.0001012677],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8052304,0.01853216,0.01460929,0.001446837,0.003185059,0.0001805383,0.0002327395,0.002281096,0.02447647,0.0003520979,0.003570909,0.1259024],"study_design_scores_gemma":[0.5381893,0.3998522,0.04765298,0.0001775138,0.002119556,0.0002909574,0.0001210501,0.001731207,0.003913054,0.0003934625,0.005524373,0.00003436293],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9948932,0.002276967,0.0001247022,0.0002302099,0.00007409871,0.0004233125,0.0004304725,0.00003374404,0.001513377],"genre_scores_gemma":[0.9942219,0.001634793,0.0002732357,0.0004550661,0.0001001813,0.0004471781,0.001270436,0.00001079554,0.001586348],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002419481,"threshold_uncertainty_score":0.008093953,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W7117293508","doi":"10.1016/j.iotech.2025.101116","title":"33P High-dimensional spatial profiling of the tumor immune microenvironment (TIME) in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) reveals predictive biomarkers of immunotherapy","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Single-cell and spatial transcriptomics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université Laval","funders":"","keywords":"Head and neck squamous-cell carcinoma; Immunotherapy; Profiling (computer programming); Tumor microenvironment; Immune system; Head and neck; Basal cell; Head and neck cancer","authors":[{"name":"F. Peyraud","is_ca":false},{"name":"J-P. Guégan","is_ca":false},{"name":"A.B. Sudaka","is_ca":false},{"name":"N. Karpinich","is_ca":false},{"name":"J. Kim","is_ca":false},{"name":"R. Cheikh","is_ca":true},{"name":"S. Yadavilli","is_ca":false},{"name":"O. Lara","is_ca":false},{"name":"O. Odin","is_ca":false},{"name":"C. Pignon","is_ca":false},{"name":"C. Rey","is_ca":false},{"name":"E.B. Saada","is_ca":false},{"name":"S. Le Moulec","is_ca":false},{"name":"A. Bessede","is_ca":false},{"name":"A. Italiano","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.00478656131430803,"gpt":0.2224617845606988,"spread":0.2176752232463908,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008408789,0.00009513283,0.00009227337,0.0002160903,0.0001411518,0.0002304072,0.00009390248,0.0001717475,0.0006459521],"category_scores_gemma":[0.0001063404,0.0001393502,0.0001008003,0.0002443194,0.0001738144,0.0001489328,0.0001337391,0.0002880786,0.000197947],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000192015,"about_ca_system_score_gemma":0.0001667477,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001081129,"about_ca_topic_score_gemma":0.002184365,"domain_scores_codex":[0.9999642,0.000004292422,0.000001534746,0.000009119005,0.0000118844,0.000008869228],"domain_scores_gemma":[0.9999603,0.00001256359,0.00001125112,0.000003528315,0.000006616733,0.000005720247],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.0000889107,0.000005443159,0.001054137,0.00002504269,0.000004287183,0.00007171638,0.00002255828,0.0004858405,0.9960843,0.0001333979,0.00007419365,0.00195009],"study_design_scores_gemma":[0.00001373472,0.000160048,0.09025331,0.00001093365,0.00003799397,0.0008362525,0.0002960533,0.009659724,0.8948017,0.0006130636,0.003299422,0.00001770055],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9849841,0.001380138,0.01101517,0.0001300531,0.00001211799,0.00001398993,0.001087783,0.0000825283,0.001294057],"genre_scores_gemma":[0.9894386,0.001131782,0.007262528,0.00004801579,0.000005874538,0.00003489597,0.0007046871,0.00003149433,0.001342135],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001081129,"threshold_uncertainty_score":0.002160966,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4405374515","doi":"10.1016/j.iotech.2024.100846","title":"103P Tislelizumab combined with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter, prospective, single-arm, real-world study","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Esophageal squamous cell carcinoma; Medicine; Chemoradiotherapy; Oncology; Basal cell; Multicenter study; Internal medicine; Carcinoma; Radiation therapy; Randomized controlled trial","authors":[{"name":"Zhihui Wen","is_ca":false},{"name":"Yuanyuan Song","is_ca":false},{"name":"Minghuan Li","is_ca":false},{"name":"Zhihong Liu","is_ca":false},{"name":"Yan Qu","is_ca":false},{"name":"Fengxia Hao","is_ca":false},{"name":"Jiajia Liu","is_ca":false},{"name":"Beilei Xu","is_ca":false},{"name":"Xueying Yu","is_ca":false},{"name":"Sheng Chen","is_ca":false},{"name":"Xiaochang Wu","is_ca":false},{"name":"Guang Cheng","is_ca":false},{"name":"Huijun Lu","is_ca":false},{"name":"Xiaolei Zhang","is_ca":false},{"name":"H. Wang","is_ca":false},{"name":"Yuqiang Cheng","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01325214264849089,"gpt":0.3187447232035502,"spread":0.3054925805550593,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008706942,0.001384118,0.004236211,0.0010858,0.0006325548,0.002035554,0.0009542811,0.00206812,0.004303317],"category_scores_gemma":[0.008670549,0.0009570773,0.009419159,0.002609313,0.0007901295,0.001647,0.0009019704,0.001534927,0.0009283774],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001187361,"about_ca_system_score_gemma":0.001418815,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001210804,"about_ca_topic_score_gemma":0.002234948,"domain_scores_codex":[0.994027,0.003254683,0.001041941,0.0008420406,0.0005733771,0.0002609192],"domain_scores_gemma":[0.9938865,0.001934294,0.00259824,0.0005209433,0.0006404195,0.000419528],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5611461,0.009741317,0.08552757,0.05896864,0.2323556,0.0006849301,0.0004778825,0.0008582693,0.003173012,0.0002553516,0.001986476,0.04482485],"study_design_scores_gemma":[0.2696197,0.129393,0.1696646,0.008245338,0.4080402,0.001332034,0.0007750478,0.001154556,0.00157664,0.0004845479,0.009462917,0.0002514595],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8106195,0.1751095,0.001425003,0.0005792037,0.0004149577,0.006280574,0.003127455,0.00006946024,0.002374281],"genre_scores_gemma":[0.9723522,0.01885472,0.001885489,0.0009510656,0.000284356,0.003332806,0.001656068,0.00001938107,0.0006639575],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008706942,"threshold_uncertainty_score":0.04604727,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4405374417","doi":"10.1016/j.iotech.2024.100929","title":"176MO ORCA-010 oncolytic therapy: Inducing tumor-specific immune responses and activation of tumor microenvironment in treatment-naïve prostate cancer","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"St. Joseph’s Healthcare Hamilton; Oakville-Trafalgar Memorial Hospital; Joseph Brant Hospital; The Scarborough Hospital; Brampton Civic Hospital","funders":"Novo Nordisk; National Institute for Health and Care Research; H. Lundbeck A/S; Cancer Research UK; Gordon and Rose McAlpine Foundation for Neuroscience Research; Francis Crick Institute","keywords":"Prostate cancer; Oncolytic virus; Immune system; Tumor microenvironment; Cancer; Medicine; Cancer research; Oncology; Immune escape; Internal medicine; Immunology","authors":[{"name":"T.D. de Gruijl","is_ca":false},{"name":"Reza Nadafi","is_ca":false},{"name":"T. Brachtlová","is_ca":false},{"name":"Jonathan Giddens","is_ca":true},{"name":"Kenneth Jansz","is_ca":true},{"name":"Peter Incze","is_ca":true},{"name":"Amitai Abramovitch","is_ca":true},{"name":"B. Shayegan","is_ca":true},{"name":"Richard Casey","is_ca":true},{"name":"Wanli Dong","is_ca":false},{"name":"Victor W. van Beusechem","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01479310649360675,"gpt":0.3085348285810627,"spread":0.2937417220874559,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009829951,0.0001366246,0.0001644744,0.00009869315,0.0001275308,0.0001774837,0.0001278119,0.0001223016,0.001780123],"category_scores_gemma":[0.00009967726,0.00007327538,0.00009985174,0.00007798213,0.0001208755,0.00008351029,0.00009162339,0.000354951,0.0001928526],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001987356,"about_ca_system_score_gemma":0.0002377622,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00100485,"about_ca_topic_score_gemma":0.001851991,"domain_scores_codex":[0.9999063,0.00001856639,0.000003862888,0.00001905428,0.00002013034,0.00003212671],"domain_scores_gemma":[0.9999702,0.000005116383,0.000004768279,0.000004642721,0.000002055826,0.00001329084],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.002062526,0.001035216,0.00408888,0.00007285621,0.00003317137,0.0002811871,0.0000961856,0.0004735803,0.9730347,0.0001903426,0.000558613,0.01807273],"study_design_scores_gemma":[0.0005963455,0.03205061,0.1042855,0.00001400807,0.0001356604,0.003150117,0.0001230788,0.004282368,0.8460802,0.0001537414,0.009109939,0.00001844082],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9983793,0.000356451,0.0001656243,0.00002598558,0.00001391428,0.00002342965,0.00007350965,0.00001814484,0.0009435829],"genre_scores_gemma":[0.9987434,0.0001042273,0.0001500458,0.00001411624,0.000004279706,0.00001731336,0.0001210276,0.000002713951,0.0008429335],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001780123,"threshold_uncertainty_score":0.0059551,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4405374727","doi":"10.1016/j.iotech.2024.100823","title":"80P Tumor markers evolution in pts treated with TCE and association with radiologic response","year":2024,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Medical Imaging and Pathology Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Cilag; Loxo Oncology; Chugai Pharmaceutical; Novartis Pharma; Genentech; PharmaMar; Basilea Pharmaceutica; Astellas Pharma; Eisai; Eisai Canada; BeiGene; Relay Therapeutics; Seagen; Agios Pharmaceuticals; Les Laboratories Pierre Fabre; Pfizer; Incyte; Boston Pharmaceuticals; Merck KGaA; Taiho Pharmaceutical; Daiichi Sankyo Europe; Servier; Foghorn Therapeutics; Gilead Sciences; Bayer HealthCare; Exelixis; Sanofi; GlaxoSmithKline; Amgen; Celgene; Institut National Du Cancer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Association (psychology); Internal medicine; Medicine; Oncology; Psychology; Psychotherapist","authors":[{"name":"Constance d’Abrigeon","is_ca":false},{"name":"Kaïssa Ouali","is_ca":false},{"name":"Noé Herbel","is_ca":false},{"name":"Stéphane Champiat","is_ca":false},{"name":"Antoine Hollebecque","is_ca":false},{"name":"C. Smolenschi","is_ca":false},{"name":"Madona Sakkal","is_ca":false},{"name":"Ratislav Bahleda","is_ca":false},{"name":"Anas Gazzah","is_ca":false},{"name":"Anna Patrikidou","is_ca":false},{"name":"Jean‐Marie Michot","is_ca":false},{"name":"Thomas Hueso","is_ca":false},{"name":"S. Ammari","is_ca":false},{"name":"Y. Loriot","is_ca":false},{"name":"C. Massard","is_ca":false},{"name":"A. Bernard-Tessier","is_ca":false},{"name":"M. Texier","is_ca":false},{"name":"C. Baldini","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.007270466107637963,"gpt":0.2744945569153401,"spread":0.2672240908077022,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00019092,0.0001397368,0.000270563,0.0004403207,0.0002016755,0.0004679876,0.0001331289,0.0003955333,0.00146074],"category_scores_gemma":[0.001563767,0.0000903336,0.0002417451,0.0004284945,0.000181736,0.000300879,0.0001898625,0.0004345365,0.0002389808],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003027871,"about_ca_system_score_gemma":0.0002008262,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001265168,"about_ca_topic_score_gemma":0.0007634549,"domain_scores_codex":[0.9998338,0.00003069885,0.00001541608,0.00003597345,0.00003139331,0.00005276089],"domain_scores_gemma":[0.9993979,0.000181247,0.0002265069,0.00002381937,0.00005565988,0.0001149012],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002727841,0.0001486572,0.9839054,0.00002180495,0.00009314166,0.0008561203,0.00009280384,0.0002533531,0.004013746,0.00005631049,0.0002464784,0.007584368],"study_design_scores_gemma":[0.00001596831,0.0006931029,0.9955715,0.000006634683,0.00007704684,0.001614456,0.0001324994,0.0004767801,0.0006962784,0.00006434786,0.0006459099,0.000005547161],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9979224,0.0004699897,0.00007882373,0.00006518509,0.000007665097,0.000005620332,0.0001553909,0.000006687524,0.0012883],"genre_scores_gemma":[0.9993218,0.00007431032,0.00002338385,0.00003051845,0.00001152331,0.000004017335,0.0001618587,0.000001889647,0.0003705827],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00146074,"threshold_uncertainty_score":0.004886627,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W7117315492","doi":"10.1016/j.iotech.2025.101210","title":"126P Neoadjuvant (neoadj) nivolumab (N) + chemotherapy (C) in patients (pts) with resectable NSCLC: Outcomes by subsequent immunotherapy (IO) in CheckMate 816","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Trinity College; McGill University Health Centre","funders":"","keywords":"Nivolumab; Chemotherapy; Immunotherapy; Chemoimmunotherapy; Neoadjuvant therapy; MEDLINE","authors":[{"name":"N. Girard","is_ca":false},{"name":"S. Lucherini","is_ca":false},{"name":"M. Provencio Pulla","is_ca":false},{"name":"M. Awad","is_ca":false},{"name":"J. Spicer","is_ca":true},{"name":"T. Mitsudomi","is_ca":false},{"name":"C. Wang","is_ca":false},{"name":"S. Lu","is_ca":false},{"name":"E. Felip","is_ca":false},{"name":"J.R. Brahmer","is_ca":false},{"name":"S. Broderick","is_ca":false},{"name":"T-E. Ciuleanu","is_ca":false},{"name":"F. Tanaka","is_ca":false},{"name":"G. Saylors","is_ca":false},{"name":"L. Lupinacci","is_ca":false},{"name":"S. Bhatia","is_ca":false},{"name":"J.L. Cai","is_ca":false},{"name":"N. Hu","is_ca":false},{"name":"P.M. Forde","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.005142110023032019,"gpt":0.2744393243525463,"spread":0.2692972143295143,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001642367,0.0001768874,0.000326293,0.0000999631,0.0001431042,0.0004411949,0.0001298559,0.0002449023,0.001565885],"category_scores_gemma":[0.0004005452,0.00008630339,0.0005184008,0.0001436967,0.0001544726,0.0003046592,0.0002217601,0.0004972481,0.0002507028],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000390971,"about_ca_system_score_gemma":0.0003686917,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001326157,"about_ca_topic_score_gemma":0.003028084,"domain_scores_codex":[0.999928,0.00001416755,0.000004062701,0.00002102946,0.000007824179,0.00002492033],"domain_scores_gemma":[0.9998423,0.00002911838,0.00003560939,0.00001118363,0.000008457091,0.00007329693],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2157743,0.002860086,0.6228862,0.0003173039,0.0007676609,0.0006248847,0.0001718219,0.00198179,0.01281125,0.0002702514,0.003685111,0.1378492],"study_design_scores_gemma":[0.005099119,0.05147898,0.9309587,0.00009771744,0.001046114,0.0006974609,0.0002370546,0.002439148,0.002729906,0.0003317851,0.004853801,0.00003034244],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9980748,0.0007167555,0.00005212038,0.00007577875,0.00003257526,0.00001411704,0.0001946788,0.000006918575,0.0008323085],"genre_scores_gemma":[0.9985525,0.0002209066,0.00005179384,0.00008970773,0.00002489565,0.00001313669,0.0004943619,0.000001590117,0.0005511467],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001565885,"threshold_uncertainty_score":0.005238354,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W7117298964","doi":"10.1016/j.iotech.2025.101461","title":"262P EGFR mutations (EGFR+) or ALK rearrangements (ALK+) in the BR31 trial of adjuvant durvalumab (D) v placebo (P)","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Canadian Cancer Society; Dalhousie University; University of Ottawa","funders":"","keywords":"Durvalumab; Placebo; Adjuvant; Mutation; Clinical trial","authors":[{"name":"T. Mimae","is_ca":false},{"name":"G. Goss","is_ca":true},{"name":"G. Darling","is_ca":true},{"name":"V. Westeel","is_ca":false},{"name":"K. Nakagawa","is_ca":false},{"name":"B. Massuti Sureda","is_ca":false},{"name":"F. Perrone","is_ca":false},{"name":"S-A. McLachlan","is_ca":false},{"name":"J.H. Kang","is_ca":false},{"name":"Y-L. Wu","is_ca":false},{"name":"A-M.C. Dingemans","is_ca":false},{"name":"R. Dziadziuszko","is_ca":false},{"name":"M. Okada","is_ca":false},{"name":"L. Greillier","is_ca":false},{"name":"C. Audigier-Valette","is_ca":false},{"name":"S. Sugawara","is_ca":false},{"name":"E. Nadal","is_ca":false},{"name":"M.R. Stockler","is_ca":false},{"name":"Ku Ke Ding","is_ca":true},{"name":"C. O'Callaghan","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01786102216622019,"gpt":0.3937564791857949,"spread":0.3758954570195747,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008306024,0.0008087553,0.001516958,0.0001410377,0.000201732,0.0007880687,0.0004433062,0.0007949807,0.004417596],"category_scores_gemma":[0.0007130791,0.0003380089,0.0008345001,0.0001461381,0.0006157972,0.0007584467,0.0002160514,0.002204323,0.0006774647],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005694841,"about_ca_system_score_gemma":0.0007318858,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00108388,"about_ca_topic_score_gemma":0.003029534,"domain_scores_codex":[0.9996294,0.0001652474,0.00001478311,0.00005484944,0.00002203551,0.0001137138],"domain_scores_gemma":[0.9997697,0.00006195532,0.00003410097,0.00002204133,0.000009822689,0.0001024082],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9401875,0.002655433,0.001216884,0.000269739,0.0005604104,0.00008696853,0.00004107727,0.0005725625,0.01036331,0.000582334,0.002600257,0.04086368],"study_design_scores_gemma":[0.8185521,0.1562403,0.01164594,0.0001151655,0.001010528,0.0003126891,0.00007887981,0.002023792,0.003272583,0.001065615,0.005644627,0.00003776064],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9885203,0.004743162,0.0003328676,0.001190406,0.0004703224,0.0002337003,0.0005660235,0.00006906875,0.003874186],"genre_scores_gemma":[0.9939579,0.001165177,0.0003205305,0.000528346,0.0001499023,0.0001084032,0.000503234,0.00001052057,0.003256112],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004417596,"threshold_uncertainty_score":0.01477832,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W7117311906","doi":"10.1016/j.iotech.2025.101202","title":"117eP In vitro assessment of an EphA2-targeting CAR-T cell therapy for NSCLC","year":2025,"lang":"en","type":"article","venue":"Immuno-Oncology Technology","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"In vitro; Radiation therapy; Cell; Cancer therapy; Cancer; Cell therapy","authors":[{"name":"R.S. Tan","is_ca":true},{"name":"N. Sereesongsaeng","is_ca":true},{"name":"R. D'Souza","is_ca":true},{"name":"A. Furness","is_ca":false},{"name":"T. Rabbitts","is_ca":true},{"name":"A. Klampatsa","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01653322237313259,"gpt":0.3857095453749428,"spread":0.3691763230018102,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005012417,0.0002960627,0.000336376,0.0002492717,0.0001752945,0.0004236965,0.0002605066,0.0004466261,0.002647212],"category_scores_gemma":[0.0002410622,0.0001539568,0.0002515662,0.0002320174,0.0001298247,0.0002242367,0.0001572648,0.0005791843,0.0006580066],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000285002,"about_ca_system_score_gemma":0.0003863591,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001949603,"about_ca_topic_score_gemma":0.002014125,"domain_scores_codex":[0.9995925,0.0001496711,0.00002712597,0.00003262902,0.0001231405,0.00007500406],"domain_scores_gemma":[0.9998853,0.00005062703,0.00000829003,0.000009568812,0.00003016049,0.00001602083],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0003701033,0.0003393152,0.0002175286,0.000117376,0.0000206985,0.0001007669,0.00005192112,0.001086368,0.9920881,0.0001931228,0.0001674248,0.005247277],"study_design_scores_gemma":[0.00003533664,0.001840462,0.0009173825,0.000005704192,0.00003540849,0.0001034104,0.00002990644,0.002763138,0.9925465,0.0000238118,0.001695024,0.000003857555],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9862393,0.002991955,0.00411347,0.0001155516,0.0000656757,0.000129028,0.0003576392,0.00004745955,0.005939866],"genre_scores_gemma":[0.9889061,0.001205597,0.00306242,0.00005087346,0.00001914431,0.0001057743,0.0006570856,0.00001390784,0.005978932],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002647212,"threshold_uncertainty_score":0.00885582,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}